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ABSTRACT 
 
 
There has been increasing concern regarding the emergence of multi-drug resistant 
pathogens. The resistance develops when pathogens, especially bacteria, are frequently exposed 
to conventional antibiotics, as they are heavily used in both human and livestock. This is due to 
the high target specificity of conventional antibiotics, which places pathogens in high selective 
pressures and eventually results in drug resistant by mutations. To address this issue, global 
actions and cooperation are needed. At the same time, new technologies and strategies need to be 
developed. Host defense peptides (HDPs) are widely found in the innate immune system. They 
show both direct antimicrobial properties and immunomodulatory activities. The multifaceted 
functions of HPDs make them less likely to promote antimicrobial resistance. Thus, they are 
promising as new therapeutics to treat multi-drug resistant infections. In fact, several drug 
candidates derived from HDPs have entered the clinical trial, but none of them got into the clinic. 
This is due to several challenges associated with HDPs, such as low in vivo stability, high cost of 
manufacturing, and toxicity to mammalian cells. In this dissertation, we explored the ability of a 
new type of unnatural scaffolds (γ-AApeptides) to mimic the functions of HDPs, including both 
broad spectrum antimicrobial properties and immunomodulatory activities. Furthermore, the 
efforts to identify simpler and more drug like γ-AApeptide based antimicrobial agents were also 
discussed. The findings in this dissertation may lead to the development of potential drug 
candidates to treat multi-drug resistant infections. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 Antibacterial Resistance (ABR) 
The emergence of antibacterial resistance has been a severe problem in recent year both 
economically and socially. It was reported by US Centers of Disease Control and Prevention 
(CDC) that the year 2013, in the US, Antibacterial Resistance (ABR) led to 20 billion dollars 
direct and 35 billion dollars indirect social costs.1 Moreover, we are facing the threat of returning 
to the pre-antibiotic era, where diseases caused by “superbugs” cannot be treated and would 
eventually lead to high mortality rates. 
Studies focused on ABR have revealed several mechanisms of resistance that bacteria 
developed, which include (1) producing enzymes, such as β-lactamases, to convert antibiotics to 
their inactive forms, (2) developing efflux pumps that can remove antibiotics from the cell before 
they reach the target sites, (3) modifying the active sites of target proteins to which antibiotics 
bind, and (4) preventing cell entry of antibiotics by altering outer membrane channels.2 
1.2 Host Defense Peptides (HDPs) 
 The heavy exposure of bacteria and other microbes to conventional antibiotics, such as β-
lactams, glycopeptides, tetracyclines, fluoroquinolones, etc, has shown strong propensity to 
promote antimicrobial resistance.3 What is the drug of last-resort to treat antibiotic resistance 
infections? Host defense peptides (HDPs) found in the innate immune system act as guards that 
can effectively combat pathogens. HDPs are generally amphiphilic peptides with more than 50% 
hydrophobic residues and overall positive charge at neutral pH. Due to this unique structural 
 2 
 
feature, HDPs can selectively bind to and interact with the negatively charged bacterial 
membrane. They are then inserted into the membrane and cause membrane disruption through 
widely accepted mechanisms, such as “barrel-stave”, “carpet”, and “torolidal-pore” 
mechanisms.4 Even though pathogens are exposed to these peptides for millions of years, this 
ancient defense mechanism doesn’t seem to promote antimicrobial resistance. 
Besides their direct antimicrobial activities, HDPs are also able to modulate immune 
responses, including pro/anti-inflammatory effects, wound healing, inducing immune cell 
differentiation, and adjuvant activities.5 Given these great properties, HDPs are promising as 
potential therapeutics to treat diseases caused by multi-drug resistant pathogens. However, 
several challenges have limited the clinical development of HDPs, such as high production cost, 
low in-vivo stability, and toxicity to eukaryotic cells. 
1.3 γ-AApeptides 
We and some other researchers have been trying to address these issues associated with 
HDPs. One alternative strategy is to use unnatural scaffolds (peptidomimetics), such as β-
peptides,6 peptoids,7 arylamides,8 etc, to mimic HDPs. Studies on peptitidomimetics have shown 
that these peptide derivatives are able to mimic the secondary structures of HDPs, which are 
critical to the anti-infective activities. Also, they are highly resistant to protease degradation, thus 
can be potentially orally available. In addition, the high chemical and structural diversities of 
peptidomimetics may lead to simpler compounds that are less costly to be manufactured yet 
exhibit higher potency and selectivity. 
γ-AApeptides are a new type of peptidomimetics recently developed in Cai’s lab.9 The 
basic building block of γ-AApeptides is an N-acylated N-aminoethyl amino acid derived from γ-
chiral peptide nucleic acid (γ-PNA). (Figure 1.1) The chiral side chain can be derived from but 
 3 
 
not limited to canonical α-amino acids. The unlimited acylation agents that can be used to 
functionalize N-acylation position give γ-AApeptides enormous chemical diversity. In addition, 
this unnatural scaffold shows resistance to protease degradation and the ability to fold into well-
defined helical structures as well. In previous studies, both linear and cyclic γ-AApeptides have 
shown potent and broad spectrum anti-infective activities.10-13 The investigation into the 
mechanisms of action revealed that they inhibit bacterial growth by disrupting bacterial 
membranes in a similar way compared to HDPs. These properties make γ-AApeptides promising 
drug candidates in the treatment of multi-drug resistant infections. 
 
 
Figure 1.1 The structures of a γ-AApeptide as comparison with an α-amino acid. 
 
1.4 Outline of the Dissertation 
Previous works on γ-AApeptides mainly focus on direct antimicrobial activities. 
However, as HDP mimics, AApeptides' immunomodulatory effects were never studied. In 
chapter 2, lipidated cyclic γ-AApeptides were investigated for their anti-infective effects by both 
direct antimicrobial and immunomodulatory activities. The dual functions would further reduce 
the chance to promote antimicrobial resistance. 
In chapter 3, we aimed to introduce short lipidated γ-AApeptides in order to develop 
more “drug-like” molecules as potential therapeutics for infections. This may shed light on the 
development of HDP based therapeutics with reduced cost of manufacturing, as high cost is one 
of the challenges to the clinical development of HDPs.  
 4 
 
Chapter 4 reports the antimicrobial activities of helical foldamers (sulfono-γ-
AApeptides). The structure-activity relationships (SARs) were studied by evaluating a helical 
foldamer library. This study may provide insights into the structural understanding of the 
interaction between γ-AApeptides and the bacterial membrane. 
In chapter 5, as a minor project, ∆9-tetrahydrocannabinol (THC) was evaluated as a 
potential therapeutic to treat Alzheimer’s disease. 
1.5 References 
 (1) US CDC 2013. 
 (2) Tenover, F. C. The American journal of medicine 2006, 119, S3. 
 (3) Afacan, N. J.; Yeung, A. T.; Pena, O. M.; Hancock, R. E. Current pharmaceutical 
design 2012, 18, 807. 
 (4) Fjell, C. D.; Hiss, J. A.; Hancock, R. E.; Schneider, G. Nature reviews. Drug 
discovery 2012, 11, 37. 
 (5) Hilchie, A. L.; Wuerth, K.; Hancock, R. E. Nature chemical biology 2013, 9, 761. 
 (6) Raguse, T. L.; Porter, E. A.; Weisblum, B.; Gellman, S. H. Journal of the 
American Chemical Society 2002, 124, 12774. 
 (7) Goodson, B.; Ehrhardt, A.; Ng, S.; Nuss, J.; Johnson, K.; Giedlin, M.; Yamamoto, 
R.; Moos, W. H.; Krebber, A.; Ladner, M.; Giacona, M. B.; Vitt, C.; Winter, J. Antimicrobial 
agents and chemotherapy 1999, 43, 1429. 
 (8) Choi, S.; Isaacs, A.; Clements, D.; Liu, D.; Kim, H.; Scott, R. W.; Winkler, J. D.; 
DeGrado, W. F. Proceedings of the National Academy of Sciences of the United States of 
America 2009, 106, 6968. 
 (9) Niu, Y.; Jones, A. J.; Wu, H.; Varani, G.; Cai, J. Organic & biomolecular 
chemistry 2011, 9, 6604. 
 (10) Niu, Y.; Padhee, S.; Wu, H.; Bai, G.; Harrington, L.; Burda, W. N.; Shaw, L. N.; 
Cao, C.; Cai, J. Chemical communications 2011, 47, 12197. 
 (11) Niu, Y.; Padhee, S.; Wu, H.; Bai, G.; Qiao, Q.; Hu, Y.; Harrington, L.; Burda, W. 
N.; Shaw, L. N.; Cao, C.; Cai, J. Journal of medicinal chemistry 2012, 55, 4003. 
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Cao, C. H.; Cai, J. F. Chem Sci 2012, 3, 2570. 
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CHAPTER 2: LIPIDATED CYCLIC γ-AAPEPTIDES DISPLAY BOTH 
ANTIMICROBIAL AND ANTI-INFLAMMATORY ACTIVITY 
 
 
Note to Reader 
 Contents in this chapter have been previously published in ACS Chem. Biol., 2014, 9 (1), 
pp 211–217, and have been reproduced with the permission of the American Chemical Society 
(ACS). 
2.1 Introduction 
 Antibiotics, as one of the greatest medical applications in the past century, have saved 
countless lives. However, widespread use of antibiotics has been counterpoised by emerging 
resistant bacteria, which can survive against an array of therapeutics.1 A recent report from the UK 
Chief Medical Officer urged haste in global research efforts to develop new antimicrobial agents 
that combat pathogens effectively, safely, and with a lower probability of eliciting bacterial 
resistance.2 As such, natural antibiotics including antimicrobial peptides (AMPs) have re-captured 
researchers’ attention. AMPs are short cationic amphiphilic peptides that exist in almost every 
living organism.3 Due to their broad-spectrum antimicrobial activity and ability to regulate the host 
immune response, AMPs appear to be a promising new class of antibiotic drug candidates.3 For 
instance, peptide antibiotics polymyxin B, gramicidin S, and nisin have been used either as over-
the-counter drugs or antibiotic food additives.3 AMPs are effective antibacterial agents due to their 
ability to form a globally amphipathic structure with segregated hydrophobic and cationic regions, 
capable of disrupting bacterial membranes.3,4 This physical mode of disruption does not readily 
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induce drug-resistance as conventional antibiotics do. 5 Additionally, AMPs are known as host 
defense peptides (HDPs) for their role in boosting host innate immunity and diminishing septic 
responses after bacterial infection.3,6 The immunomodulatory activities of AMPs may be their most 
crucial contribution to host defense, since the direct antimicrobial activity of AMPs is often weak 
under physiological conditions.3,7,8 One of the most important immune responses against bacterial 
infection is LPS activated TLR4 signaling. LPS is a characteristic component of Gram-negative 
bacterial cell walls, and activates the immune response through TLR4. Gram-negative bacterial 
infection is of critical health importance, as it can result in septic shock and even death.6 As such, 
AMPs have dual roles as both novel antibiotic and anti-sepsis agents in the treatment of bacterial 
infections.  
Despite the many advantages of AMPs, they are susceptible to proteolytic cleavage and 
often have moderate antimicrobial activity, making their development as therapeutics difficult. 
Peptidomimetics, which contain modified peptide backbones, are more stable against protease 
degradation, and may be synthetically modified to develop more potent antimicrobial agents. 
Examples of successful antimicrobial peptidomimetics include β-peptides9-11 and peptoids.12-17 5,18-
29 Similar to AMPs, these peptidomimetics are designed to form globally amphipathic structures 
upon interaction with bacterial membranes, facilitating disruption of their membranes. Although 
many peptidomimetics have broad-spectrum antibacterial activity, the reports of 
immunomodulatory responses are very rare.28,29 Anguita and Tew et al29 identified AMP mimics 
which antagonize lipoteichoic acid (LTA) activated Toll-like receptor 2 (TLR2) signaling; 
however, these compounds either agonize lipopolysaccharide (LPS) induced TLR4 responses,28 or 
have relatively weak suppressing effect on TLR4 activation.29 Additionally, these AMP mimics 
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bind directly to LTA, preventing ligand activation of TLRs. Here we present a new class of 
immunomodulatory peptidomimetics, which inhibit TLR signaling without ligand interaction. 
We recently developed a new class of peptidomimetics termed “γ-AApeptides”.30-35 Due 
to the versatility of γ-AApeptides, we were able to synthesize potent antimicrobials with broad-
spectrum activity against both Gram-positive and Gram-negative bacteria.23,26,27,36 The design of 
antimicrobial γ-AApeptides is straightforward, and synthesis is achieved through joining of 
amphipathic γ-AApeptide building blocks. Currently, we report the design and synthesis of a new 
class of antimicrobial γ-AApeptides - lipidated cyclic γ-AApeptides. We show that this class of 
compounds has potent and broad-spectrum antimicrobial activity against both Gram-positive and 
Gram-negative bacteria, including community-acquired multidrug-resistant pathogens. In addition, 
several lipidated cyclic γ-AApeptides inhibit Toll-Like Receptor 4 (TLR4) signaling and block 
production of harmful proinflammatory cytokines such as tumor necrosis factor-α (TNF-α). To the 
best of our knowledge, these lipidated cyclic γ-AApeptides are the most potent reported 
antimicrobial peptidomimetics that prevent the induction of TNF-α by the TLR4 ligand LPS. As 
such, lipidated cyclic γ-AApeptides may have the potential to become a new generation of 
antibiotic agents through direct bacteria killing, as well as a new class of anti-septic agents through 
immunomodulation.  
2.2 Results and Discussion 
We have shown previously that cyclization26 or lipidation27 can lead to more potent 
antimicrobial agents. Cyclization reduces the motility of amphipathic structures which facilitate 
bacterial membrane disruption;26 while lipidation makes encourages antimicrobial agents to 
interact with membranes.27 We therefore speculated that γ-AApeptides that are both cyclized and 
lipidated would be more potent in killing bacterial pathogens. In fact, lipidated cyclic peptides 
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polymyxin37 and daptomycin38 have been used as “last-resort” antibiotics to treat infections caused 
by Gram-negative and Gram-positive bacteria, respectively. However, it should be noted that these 
two lipidated cyclic peptide antibiotics are not AMPs, as they do not disrupt bacterial membranes, 
and as such have reduced broad-spectrum activity against multiple bacterial families. Based on 
previous results,16 we expect that amphiphilic lipidated cyclic γ-AApeptides are  able to disrupt 
bacterial membranes,26,27 and therefore, they will be active against both drug-resistant Gram-
positive and Gram–negative bacteria. To test our hypothesis, a series of lipidated cyclic γ-
AApeptides (Figure 2.1) containing different numbers of amphiphilic γ-AApeptide building 
blocks were designed and synthesized on the solid phase (See supporting information for synthetic 
details). Their antibacterial activity was then measured against a range of multi-drug resistant 
Gram-negative and Gram-positive bacteria (Table 2.1). 
We initially designed and synthesized lipidated cyclic γ-AApeptides (HW-B-73, -77 and -
78, Figure 2.1) in which the lipid tail C16 is directly connected to the ring structure. Unfortunately, 
these sequences only possess weak activity against bacteria, and are less effective than previously 
reported cyclic γ-AApeptides without lipid tails.26 We hypothesize that this is because the lipid tail 
on the ring structure has limited flexibility, and cannot position itself for membrane insertion even 
after the amphipathic ring contacts the bacterial membrane. Indeed, a trend was apparent in other 
membrane-active lipidated cyclic peptide antibiotics, including daptomycin and polymyxin B, 
which contain at least two amino acid residues connecting both lipid tails and ring structures. To 
test our hypothesis, we moved the lipid tail outside the cyclic ring, leading to sequence YL-1. As 
expected, YL-1 shows strong activity against Gram-positive bacteria, although it only contains 
three amphiphilic building blocks. However, the addition of one more amphiphilic building block 
to the ring (YL-4) does not boost activity. We speculate that since the lipid tail may be the 
10 
 
determinant component for the overall activity, the contribution of the amphiphilic ring structure 
can be saturated. In fact, YL-4 has weaker activity than YL-1, which may due to the increased 
flexibility of the larger ring compared with that of YL-1. This trend is also seen for HW-B-77 and 
HW-B-78, which are even less active than the smaller HW-B-76. 
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Figure 2.1 The structures of lipidated cyclic γ-AApeptides synthesized on the solid phase. 
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Table 2.1 The antimicrobial and hemolytic activities of lipidated cyclic γ-AApeptides. The 
microbial organisms used are E. coli (ATCC 25922), K. pneumoniae (ATCC 13383), P. 
aeruginosa (ATCC 27853), Methicillin-resistant S. epidermidis (RP62A), Vancomycin-resistant 
E. faecalis (ATCC 700802), and Methicillin-resistant S. aureus (ATCC 33591). The minimum 
inhibitory concentration (MIC) is the lowest concentration that completely inhibits growth after 
24 h. HC50 is the concentration causing 50% hemolysis. Pexiganan28,39 and previously reported 
cyclic γ-AApeptide HW-B-1326 are included for comparison (data are from cited references).  
 
Oligomers MIC (µg/mL) Hemolysis
Gram-negative Gram-positive
E. coli K. 
pneumoniae 
P. 
aeruginosa 
S. epidermidis E. faecalis S. aureus HC50
HW-B-73 >25 20 >25 20 >25 20 - 
HW-B-77 >25 20 >25 >25 >25 >25 - 
HW-B-78 >25 20 >25 >25 >25 >25 - 
YL-1 >25 8 20 2 5 5 250 
YL-4 >25 >25 >25 >25 >25 >25 250 
YL-12 5 5 10 5 5 10 180 
YL-29 >25 10 25 5 5 5 150 
YL-34 10 3 10 1 2 2 200 
YL-36 2 3 5 1 3 2 100 
HW-B-13 20 8 8 2 5 1 100 
Pexiganan 8 8 16 8 32 16 120 
 
 
We have previously noticed that the precise amphiphilicity can affect the antimicrobial 
activity of a sequence.24 The reversal of cationic and hydrophobic groups results in antimicrobial 
agents with different potency.24 As such, YL-12, containing one reversed amphiphilic building 
block in relation to YL-1, was prepared. This sequence has improved antimicrobial activity against 
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both Gram-negative and Gram-positive bacterial strains. The reversal of additional building blocks 
leads to the most potent lipidated cyclic γ-AApeptides YL-34 and YL-36. Particularly, YL-36 
contains a small amphipathic ring and a C16 lipid tail, and has very potent activity against all tested 
drug-resist Gram-positive and Gram-negative strains. It not only has improved antimicrobial 
activity than the AMP Pexiganan, but is also superior when compared with the previously reported 
cyclic γ-AApeptide HW-B-13.  
We hypothesize that lipidated cyclic γ-AApeptides are able to kill bacteria through 
membrane disruption analogous to AMPs, as they possess globally cationic amphipathic structures 
and broad-spectrum activity against both Gram-positive and Gram-negative bacteria. As such, a 
fluorescence microscopy experiment was carried out to study the ability of the most potent lead 
YL-36 to affect the membranes of S. aureus (Gram-positive) and E. coli (Gram-negative). Briefly, 
both bacteria were stained with membrane permeable dye 4',6-diamidino-2-phenylindole (DAPI) 
and non-permeable dye propidium iodide (PI) in the absence or presence of YL-36 (Figure 2.2). 
YL-36 treatment resulted in PI becoming visible using fluorescence microscopy, suggesting 
bacterial membranes of both S. aureus and E. coli were damaged.  Aggregation of S. aureus after 
treatment with YL-36 is observed, which is generally believed to arise from the loss of membrane 
potential after the disruption of membranes.23-27,36 
In addition to bacterial membrane disruption, some AMPs are capable of modulating the 
immune system through TLR signaling. As such, YL-1, YL-12, YL-29, YL-34, and YL-36 were 
assessed for the ability to modulate the LPS-induced TLR4 signaling response by measuring nitric 
oxide production (Figure 2.3a).40 Nitric oxide is produced as a downstream inflammatory factor in 
all TLR signaling. Inhibition of reactive nitrogen species is critical for control of a global 
inflammatory response. Figure 2.3a shows that lipidated cyclic γ-AApeptides are a potent class of 
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anti-TLR 4 signaling agents, capable of reducing nitric oxide production. To further investigate 
the anti-inflammatory capabilities of lipidated cyclic γ-AApeptides, we chose the most potent 
antimicrobial agent YL-36 for further investigation. The EC50 of YL-36 was obtained by treating 
RAW 264.7 cells with varying concentrations of YL-36 in concert with 20 ng/mL LPS. The 
resulting inflammation was measured with a nitric oxide assay after 24 hours. 
 
 
Figure 2.2 Fluorescence micrographs. S. aureus (A) and E. coli (B) are treated/(or no treatment) 
with 5 µg/ml lipidated cyclic γ-AApeptide YL-36 for 2 h. a1, control, no treatment, DAPI stained; 
a2, control, no treatment, PI stained; b1, YL-36 treatment, DAPI stained; b2, YL-36 treatment, PI 
stained. 
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Figure 2.3 Inflammatory response of RAW 264.7 cells in the presence of inhibitors. a. Nitric oxide 
production in the presence of the lipidated cyclic γ-AApeptides YL-1, YL-12, YL-29, and YL-34. 
RAW 264.7 cells were treated with 20 ng/mL LPS and varying concentrations of lipidated cyclic 
γ-AApeptides in a 96-well plate. Data is normalized to 20 ng/mL LPS as 100% activation, and 
untreated cells as 0% activation. b. Dose-dependent inhibition of nitric oxide production by YL-
36. This experiment was performed as described in part a, and a dose response curve was obtained 
for calculation of an IC50 value. 
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Figure 2.3b shows that YL-36 has a nitric oxide signaling IC50 of 1.98 μM, which is one 
of the most potent TLR4 peptidomimetic inhibitors reported to date. Additionally, YL-36 is non-
toxic up to 100 μM (Figure 2.4), suggesting the inhibition of nitric oxide is not due to the toxicity 
of YL-36. As such, we further explored the ability of YL-36 to inhibit NF-κB activation and the 
production of pro-inflammatory cytokines. NF-κB activation is inhibited with an EC50 of 1.02 μM 
(Figure 2.5a) as determined with a secreted embryonic alkaline phosphatase (SEAP) assay.41 NF-
κB activation is directly correlated to TLR activation, as signaling results in NF-κB nuclear 
translocation. Furthermore, the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) is also 
strongly inhibited (Figure 2.5b).42 This result suggests that NF-κB regulated genes can be inhibited 
with YL-36 treatment.  
 
 
Figure 2.4 YL-36 is non-toxic with treatments up to 100 μM as demonstrated by a Crystal Violet 
cell viability assay. Data is normalized with untreated cells as 100% survival, and blank wells as 
0% survival. 
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Figure 2.5 Anti-inflammatory effect of YL-36 by inhibiting both NF-κB transcription and TNF-α 
production. a. NF-κB activation in HEK 293 cells in the presence of YL-36. HEK 293 cells were 
stably transfected with TLR4, MD2, CD14, and a secreted embryonic alkaline phosphatase (SEAP) 
reporter gene. Cells were plated in 96-well plate with 40,000 cells/well and treated with 20 ng/mL 
LPS and 3. Data is normalized to 20 ng/mL LPS as 100% activation, and untreated cells as 0% 
activation. Increasing concentrations of YL-36 decrease NF-κB transcription of SEAP in a dose-
dependent fashion. b. YL-36 reduces production of TNF-α. TNF-α production was measured with 
a monoclonal mouse ELISA. Data is normalized to 20 ng/mL LPS as 100% activation, and 
untreated cells as 0% activation. Increasing concentrations of YL-36 result in decreased production 
of TNF-α, suggesting an anti-inflammatory effect. 
 
 
Figure 2.6 YL-36 inhibits TLR4 activation without binding to LPS. Raw 264.7 cells were 
incubated for 30 minutes with 10 μM YL-36. After incubation, pre-treatment cells were washed 
with medium and activated with 20 ng/mL LPS. Co-treatment cells were not washed, and were 
treated with 20 ng/mL LPS while YL-36 remained in the medium. Antagonism for both cell 
treatments is 100%, suggesting at YL-36 does not bind to the ligand as a mode of inhibition. Data 
is normalized to 20 ng/mL LPS as 100% activation, and untreated cells as 0% activation. 
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Previously identified antimicrobial agents reduce TLR-induced inflammation through 
binding to specific TLR ligands. However, cyclic γ-AApeptides do not appear to interact with the 
ligand as a mechanism of inhibition (Figure 2.6). Our data demonstrates that both pre-treatment 
and co-treatment with γ-AApeptides and LPS results in complete antagonism of nitric oxide 
production. This indicates that γ-AApeptides reduce inflammation through a novel mechanism 
which does not involve the binding to TLR ligands, and may simultaneously combat bacterial 
infection and reduce inflammation. 
2.3 Conclusions 
As a new class of antimicrobial peptidomimetics that mimic AMPs, lipidated cyclic γ-
AApeptides exhibit potent and broad-spectrum activity against a range of multi-drug resistant 
Gram-negative and Gram-positive bacteria. More importantly, they also display unique 
immunomodulatory capabilities similar to AMPs. Lipidated cyclic γ-AApeptides have been shown 
to antagonize the LPS activated TLR4 NF-κB signaling response, and to potently suppress release 
of harmful pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α). To the best of 
our knowledge, these lipidated cyclic γ-AApeptides are the most potent antimicrobial 
peptidomimetics that prevent the production of LPS-induced TNF-α.  Additionally, lipidated 
cyclic γ-AApeptides do not bind to TLR ligands, suggesting a novel mechanism for 
immunomodulation. These peptidomimetics provide an exciting new approach to treat bacterial 
infections by exerting dual-functional roles: they are a new generation of antibiotic agents that kill 
both multi-drug resistant Gram-positive and Gram-negative bacteria directly, as well as novel anti-
sepsis agents through harnessing immune responses.  
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2.4 Experimental Section 
2.4.1 General experimental materials 
Rink amide MBHA resins (200-400 mesh, 0.7 mmol/g) were purchased from Chem-
Impex Int’l Inc and any other chemicals were ordered from either Sigma-Aldrich or Fisher 
Scientific. 1H NMR spectra of the building blocks were run on the Varian Inova 400 instrument 
at University of South Florida. The solid phase syntheses of the lipidated cyclic γ-AA peptides 
were done in a peptide reaction vessel on a Burrell Wrist-Action shaker, and the peptides were 
analyzed and purified using an analytical and preparative Waters HPLC system. The final 
products were dried in a Labcono lyophilizer. Molar masses were identified using the Bruker 
AutoFlex MALDI-TOF mass spectrometer. 
2.4.2 Synthesis and characterization of the lipidated cyclic γ-AA peptides building blocks 
The building blocks (Figure 2.7) were synthesized in the same published ways43-45, and 
the 1H NMR data of structures which have not been reported (1, 5, 6) are shown below. 
Compound 1. Yield 60%. 1H NMR (CDCl3, 800 MHz) δ (two rotamers) 7.71 (d, J = 8 Hz, 2H), 
7.55 (d, J = 8 Hz, 2H), 7.35 (t, J = 8 Hz, 2H), 7.27 (t, J = 8 Hz, 2H), 4.70-4.26 (m, 3H), 4.14-
4.02 (m, 2H), 3.85-3.33 (m, 3H), 3.05 -2.99 (m, 2H), 2.33-2.17 (m, 2H), 1.52-1.40 (m, 15H), 
1.24-1.15 (m, 24H) ppm. 13C NMR (CDCl3, 200 MHz) δ (two rotamers) 175.3, 156.9, 156.2, 
143.9, 143.8, 141.2 127.6, 127.0, 125.2, 119.9, 79.2, 66.9, 66.7, 50.5, 50.2, 47.2, 47.1, 40.2, 33.2, 
32.5, 31.9, 29.7, 29.6, 29.4, 28.4, 25.1, 22.7, 14.2, 14.1 ppm. HR-ESI: [M+H]+ calc: 750.5052, 
found: 750.5069. 
Compound 5. Yield 60%. 1H NMR (CDCl3, 800 MHz) δ (two rotamers) 7.74 (t, J = 8 Hz, 2H), 
7.52-7.45 (m, 2H), 7.38 (t, J = 8 Hz, 2H), 7.29-7.15 (m, 7H), 4.33 (t, J = 8 Hz, 1H), 4.22-4.12 
(m, 2H), 4.06-3.99 (m, 3H), 3.75-3.24 (m, 2H), 2.97-2.76 (m, 2H), 2.21-2.17 (m, 2H), 1.54-1.52 
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(m, 2H), 1.24-1.16 (m, 24H), 0.88 (t, J = 8 Hz, 3H) ppm. 13C NMR (CDCl3, 200 MHz) δ (two 
rotamers) 175.7, 175.6, 172.6, 171.9, 156.8, 155.9, 143.8, 143.7, 143.5, 141.2, 141.1, 137.1, 
136.9, 131.2, 128.6, 127.0, 125.3, 125.2, 125.0, 124.9, 120.0, 119.9, 52.6, 52.3, 51.8, 50.4, 49.0, 
46.9, 38.7, 38.0, 33.1, 32.6, 31.9, 29.7, 29.6, 29.4, 25.0, 22.7, 14.2 ppm. HR-ESI: [M+H]+ calc: 
669.4262, found: 669.4269. 
Compound 6. Yield 60%. 1H NMR (CDCl3, 800 MHz) δ (two rotamers) 8.65 (s, 2H), 7.75 (d, J = 
8 Hz, 2H), 7.57 (d, J = 8 Hz, 2H), 7.38 (t, J = 8 Hz, 2H), 7.30 (t, J = 8Hz, 2H), 5.89-5.81 (m, 
1H), 5.29-5.25 (m, 1H), 5.21-5.18 (m, 1H), 4.52 (d, J = 8 Hz, 2H), 4.35-4.12 (m, 3H), 3.76 (s, 
2H), 3.64-3.39 (m, 1H), 3.28-2.97 (m, 4H), 2.73-2.44 (m, 4H), 1.57-1.42 (m, 15H) ppm. 13C 
NMR (CDCl3, 200 MHz) δ (two rotamers) 173.7, 173.2, 172.9, 172.8, 172.7, 159.9, 159.6, 
158.6, 157.0, 156.7, 156.5, 143.8, 143.7, 143.5, 143.4, 141.2, 131.9, 131.8, 127.8, 127.1, 127.0, 
125.2, 125.0, 124.9, 120.0, 119.9, 118.6, 118.5, 118.1, 67.6, 67.3, 65.5, 52.0, 51.4, 51.1, 50.6, 
50.2, 47.0, 40.7, 39.9, 32.1, 31.3, 29.4, 29.1, 28.3, 27.8, 27.5, 22.6 ppm. HR-ESI: [M+H]+ calc: 
652.3229, found: 652.3255. 
2.4.3 Solid phase synthesis, purification and characterization of lipidated cyclic γ-AA peptides 
The syntheses of our lipidated cyclic γ-AA peptides are based on building blocks strategy 
as reported in previous papers44,45. For each coupling cycle, we used 20% Piperidine in DMF to 
remove the Fmoc protecting group, and 1.5 equiv. of building blocks with 4 equiv. of HOBT (1-
hydroxybenzotriazole monohydrate)/DIC (diisopropylcarbodiimide) in DMF for 6 hours. The 
cyclization was done on the resins with the aid of building block 2. Before the cyclization, the 
allyl group was removed by 0.2 equiv of Pd(PPh3)4/10 equiv of PhSiH3/CH2Cl2 (2hours for each, 
repeated twice). The exposed carboxyl group will react with the N-terminus of the sequence to 
form the intramolecular circle after another deprotection of the Fmoc, and the cyclization was 
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completed using PyBOP/HOBT/DIPEA/DMF. After that, the cleavage of the peptides from solid 
support was done in 50:48:2 TFA/CH2Cl2/TIS (triisopropylsilane) for 2 hours. The solvents were 
evaporated and the sequences were analyzed and purified using a Waters HPLC system and the 
traces were detected at 215 nm (Figure 2.8). The lyophilized compounds were collected and their 
molecular weights were shown below (Table 2.2) using Bruker AutoFlex MALDI-TOF mass 
spectrometer using α-cyano-4-hydroxy-cinnamic acid. 
 
Figure 2.7 Structures of lipidated cyclic γ-AA peptides building blocks. 
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Figure 2.8 The synthesis and structures of lipidated cyclic γ-AApeptides. 
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Table 2.2 MALDI analysis of lipidated cyclic γ-AA peptides. 
Lipidated Cyclic γ-
AA peptides 
Yield (based on resin 
loading) 
Molecular Weight 
(Actual) 
Molecular Weight 
(found) 
YL-1 12.0% 1608.09 1661.941 (M+3NH4+) 
YL-4 9.8% 1911.29 1965.442 (M+3NH4+) 
YL-12 10.1% 1580.06 1634.593 (M+3NH4+) 
YL-29 9.7% 1827.19 1828.014 (M+H+) 
YL-30 11.0% 1855.23 1909.426 (M+3NH4+) 
YL-34 11.3% 1552.03 1605.503 (M+3NH4+) 
YL-36 9.7% 1524.00 1525.010 (M+H+) 
HW-B-73 8.5% 1608.11 1609.388 (M+H+) 
HW-B-77 8.0% 1911.29 1912.755 (M+H+) 
HW-B-78 8.3% 2214.48 2216.346 (M+H+) 
 
2.4.4 Antimicrobial assays 
We tested our lipidated cyclic γ-AA peptides on various microbial organisms like B. 
subtilis (BR151), multiple-drug resistant S. epidermidis(MRSE, PR62A), C. albicans 
(ATCC10231), Vancomycin-resistant E. faecalis (ATCC 700802), Methicillin-resistant S. aureus 
(ATCC 33592), K. pneumonia (ATCC 13383), multi-drug resistant P. aeruginosa 
(ATCC27853). The highest concentration of our tested AA-peptides was 50 μg/ml and the 
minimum inhibitory concentration (MIC) was measured on the bacteria growing for 24 hours. In 
order to get the MIC, we grew the bacteria in 5 ml of medium at 37 oC overnight for this period 
of growing gave a suspension of approximate 5.0 × 105 CFU/ml. The test compounds were 
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stocked in PBS buffer (1mg/ml) and then further diluted in medium using two-fold serial dilution 
method (0.5-100 µg/ml). Aliquots of 50 µl of bacterial suspension were mixed with 50 µl of 
medium containing different concentrations of cyclic γ-AA-peptides, which make the total 
volume 100 µl for each well in the sterile 96-well plate. The plate was incubated at 37 oC 
overnight with cell growth monitored by a Biotek Synergy HT microtiter plate reader under 600 
nm wavelength46. MIC was determined when the lowest concentration of the compounds inhibit 
the cell growth completely. The results were repeated three times with duplicates for each time. 
2.4.5 Hemolysis assay 
Freshly drawn, K2 EDTA treated human red blood cells (hRBCs) was washed with PBS 
buffer for a couple of times and centrifuged at 1000g for 10 minutes each time, and a clear 
supernatant was observed44,45. After removing the supernatant, the cell pellets were resuspended 
in PBS, and then mixed with serial diluted γ-AA cyclic peptides in a 96-well plate. 0% hemolysis 
(negative control) was determined by mixing blood with PBS and 100% hemolysis (positive 
control) was determined by mixing blood with Triton X-100 (final concentration 0.1%). The 
plate was incubated at 37 oC for 1h and centrifuged at 3500 rpm for 10 min44. The supernatant 
was taken out and diluted in PBS, and the absorbance was detected at 360 nm using a Biotek 
Synergy TH plate reader. A hemolysis curve can be got in this way and therefore it would be 
able to evaluate the hemolytic toxicity of the tested compounds. 
% hemolysis = (Abssample – AbsPBS)/(AbsTriton - AbsPBS)*100% 
2.4.6 Fluorescence microscopy 
We used the double staining method with DAPI (4’, 6-Diamidino-2-phenylindole 
dihydrochloride, Sigma, >98%) and PI (Propidium iodide, Sigma) to dye the bacteria cells like E. 
coli or B. subtilis. DAPI is a DNA binding dye which can stain all bacterial cells regardless of 
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their viabilities, and PI is an ethidium derivative which only passes through dead cells membrane 
and intercalates with their nucleic acids, forming fluorescent complexes. Mid-logarithmic phase 
bacteria were incubated with lipidated cyclic γ-AA peptides for 2 hours, and then were 
centrifuged at 3000g for 15 minutes to get the pellets. The bacteria cell pellets were washed with 
PBS and then incubated with PI, followed by washing and incubation with DAPI (each dye 
incubation is performed at 0 oC for 15 minutes in dark). Controls were bacteria culture without 
peptides following the same procedure described above. The stained bacteria cells were observed 
under Zeiss Axio Imager Zloptical microscope using the 100X oil-immersion objective. 
2.4.7 Fluorescent detection of nitric oxide 
Raw 264.7 (Mouse leukaemic monocyte macrophage cell line) cells were grown in RPMI 
1640 medium containing 1% L-glutamine, 1% Penicillin/streptomycin and 10% fetal bovine 
serum (FBS). Cells were plated in a 96-well plate at 75,000 cells/well in complete RPMI 1640 
medium, and allowed to grow overnight at 37°C and 5% CO2 in a humidified incubator. The 
media was removed, and cells were placed in unsupplemented RPMI 1640 medium. 20 ng/mL 
LPS and the appropriate concentration of lipidated cyclic γ-AApeptides (20 mM stock solutions 
in PBS) were added to a final volume of 200 μL. PBS controls were included in each experiment. 
Plates were then incubated for 24 h, and then 100 μL of media was transferred to a flat black 96-
well microfluor plate (Thermo Scientific, MA, USA). Following that, 10 μL of 0.05 mg/mL 2,3-
diaminonamthalene in 0.62 M HCl was added to the media and incubated for 20 minutes in the 
dark. The reaction was quenched with 5 μL of 3.0 M NaOH, and the plate was read on a 
Beckman Coulter DTX880 plate reader (Beckman Coulter, CA, USA). Data was collected with 
excitation at 360 nm and emission at 430 nm. Data was normalized with the ligand only control 
as 100% activation, and the untreated cells as 0% activation. Fold inhibition = [(Sample 430 nm 
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– Untreated cells 430 nm)/(Ligand Control 430 nm – Untreated cells 430 nm)]. The EC50 values 
were calculated graphically using OriginPro v8.6 software. 
2.4.8 Secreted embryonic alkaline phosphatase (SEAP) reporter of NF-κB transcription 
HEK293 (Human Embryonic Kidney 293) cells were grown in Dulbecco’s Modified 
Eagle Medium (DMEM) in the presence of 1% Penicillin/streptomycin, 10% fetal bovine serum 
(FBS), and 1% L-glutamine. HEK293 cells are stably transfected with human TLR4, as well as 
the required accessory proteins MD-2 and CD14. Moreover, the cells also possess an optimized 
alkaline phosphatase reporter gene under the control of a NF-κB inducible promoter. (10) Cells 
were first plated in a 96-well plate at 40,000 cells/well in complete DMEM medium and allow to 
grow overnight at 37°C and 5% CO2 in a humidified incubator. Then the media was removed, 
and cells were placed in Optimem + 0.5% FBS medium. 20 ng/mL LPS and the appropriate 
concentration of lipidated cyclic γ-AApeptides were added to a final volume of 200 μL. PBS 
buffer was included as control. Plates were then incubated for 24 h, and then medium was 
assayed per the instructions of the Phospha-Light™ SEAP Reporter Gene Assay System 
(Applied Biosystems, NY, USA). The plate was read on a Beckman Coulter DTX880 plate 
reader (Beckman Coulter, CA, USA). Data was collected with luminescence at 430 nm. Data 
was normalized with the ligand only control as 100% activation, and the untreated cells as 0% 
activation. Fold inhibition = [(Sample 430 nm – Untreated cells 430 nm)/(Ligand Control 430 
nm – Untreated cells 430 nm)]. The EC50 values were calculated graphically using OriginPro 
v8.6 software. 
2.4.9 Enzyme-linked immunosorbent assay (ELISA) detection of TNF-α 
Raw 264.7 (Mouse leukaemic monocyte macrophage cell line) cells were grown in RPMI 
1640 medium with 10% fetal bovine serum (FBS), 1% Penicillin/streptomycin, and 1% L-
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glutamine. Cells were plated in a 96-well plate at 75,000 cells/well in complete RPMI 1640 
medium and allowed to grow overnight at 37°C and 5% CO2 in a humidified incubator. Then 
media was removed, and cells were placed in unsupplemented RPMI 1640 medium. 20 ng/mL 
LPS and the appropriate concentration of lipidated cyclic γ-AApeptides (20 mM stock solutions) 
were added to a final volume of 200 μL. PBS was included as the control. Plates were then 
incubated for 24 hours, and then samples were assayed for TNF-α per the method outlined in the 
BD Biosciences Mouse TNF (Mono/Mono) ELISA Set (BD Biosciences, CA, USA). The plate 
was read on a Beckman Coulter DTX880 plate reader (Beckman Coulter, CA, USA). Data was 
collected with absorbance at 450 nm. Data was normalized with the ligand only control as 100% 
activation, and the untreated cells as 0% activation. Fold inhibition = [(Sample 450 nm – 
Untreated cells 450 nm)/(Ligand Control 450 nm – Untreated cells 450 nm)]. The EC50 values 
were calculated graphically using OriginPro v8.6 software. 
2.4.10 Crystal violet toxicity assay 
Cells which were treated with compound for nitric oxide experimentation were also 
tested for compound toxicity using crystal violet stain. Cells were fixed for 20 minutes in 4% 
paraformaldehyde after the media was removed. After fixing, formaldehyde was removed and 
cells were incubated for 1h with 0.05% crystal violet stain. After incubation, cells were rinsed 
with deionized water and reconstituted in 100% methanol for 10 minutes. The plate was read on 
a Beckman Coulter DTX880 plate reader (Beckman Coulter, CA, USA). Data was collected with 
absorbance at 535 nm. Data was normalized with the untreated cells control as 100% survival, 
and the blank wells as 0% survival. Fold inhibition = [(Sample 535 nm – Blank 535 
nm)/(Untreated cells 535 nm – Blank 535 nm)].  
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CHAPTER 3: SHORT ANTIMICROBIAL LIPO-α/γ-AA PEPTIDES 
 
 
Note to Reader 
 Contents in this chapter have been previously published in ChemBioChem, 2014, 15, 
2275-2280, and have been reproduced with the permission of John Wiley and Sons. 
3.1 Introduction 
The emerging antibiotic resistance is one of the most serious public concerns.1 Host-
defense peptides (HDPs), natural cationic antimicrobial peptides, have attracted considerable 
interest because they generally kill bacterial pathogens by disrupting bacteria membranes.2 Such 
a mode of action is rather a physical force and generally lacks specific membrane or cellular 
targets in bacteria. 3 As the result, they may possess less probability to elicit antibiotic 
resistance.4 Meanwhile, the selectivity of HDPs remains high because bacteria membranes are 
more negatively charged on their outer lipid membrane leaflet compared to those of mammalian 
cells. This has led to significant effort in the development of HDPs and their analogous as novel 
antibiotic agents to combat antibiotic resistance. However, HDPs are associated with intrinsic 
drawbacks including susceptibility to proteolytic degradation, poor selectivity and low-to-
moderate activity. One of the approaches to address these issues is to develop peptidomimetics 
that can mimic the mechanism of action of HDPs. To date, there are a range of classes of 
peptidomimetics have been explored for their antimicrobial activity, such as peptoids,5 β-
peptides,6 peptoid-peptide hybrids,7 arylamides.8 However, most antimicrobial peptidomimetics 
have fairly large sizes, posing great challenge for production due to multi-step synthesis and 
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structure complexity. As such, a number of groups have started to develop antimicrobial 
peptidomimetics9,10 which are smaller in size while still retain good and broad-spectrum activity.  
We recently have developed a new class of peptidomimetics termed “γ-AApeptides”, as 
they are oligomers of N-acylated-N-aminoethyl amino acids (Figure 3.1).11 As half of side 
functional groups are from any acylating agents including carboxylic acids or acyl chlorides, the 
chemical diversity of γ-AApeptides is limitless.11,12 Additionally, they have shown to be highly 
resistant to proteolytic degradation.11,13 These features make γ-AApeptides a promising 
peptidomimetics for the mimicry the structure and function of bioactive peptides.13-15 Indeed, a 
variety of γ-AApeptides have been developed in our group to mimic the global amphipathic 
structure of HDPs, and these molecules display potent and broad-spectrum antimicrobial activity 
against an array of antibiotic resistant Gram-positive and Gram-negative bacteria.1,4,16-19 
However, most lead γ-AApeptides are all fairly long sequences and thus require a number of 
steps to synthesize. We believe it is considerably significant if short antimicrobial γ-AApeptides 
can be developed, which would further enhance their potential application.  
 
Figure 3.1 The structure of γ-AApeptide in comparison to an α-peptide. 
Lipidation on short cationic peptides or peptoids have led to antimicrobial agents with 
potent activity.9 20,21 This is because hydrophobic lipid tail increases the lipophilicity of 
molecules and enhances the interaction between molecules and bacterial membranes. As such, 
short sequences could become active. Moreover, a few research groups have reported the study 
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of peptidomimetic-α hybrid peptidic oligomers for their antimicrobial activity, which reveals 
unexpected potency and low hemolytic activity.7 22 Although the real mechanism is not known, 
these results suggest that short lipidated peptidomimetic-α hybrid peptidic oligomers may be also 
potentially active and selective against bacteria.  
3.2 Results and Discussion 
To test our hypothesis, we synthesized a focused library of short lipidated α/γ-AA hybrid 
peptides following our previously reported protocol.12,16,18 These chimeric peptides only contain 
either one or two cationic γ-AApeptide building blocks in addition to one lysine amino acid 
residue (Figure 3.2). Thus, they synthesis is very convenient. In addition, cationic γ-AApeptide 
building blocks are composed of either two cationic charges, or one cationic group and one 
hydrophobic group. As such, their overall global structures are still expected to be amphipathic, 
which mimics those of HDPs. To investigate the impact of number of lipid tails on the activity, 
one or two C16 tails are introduced to the N-terminus or both α- and ε-NH2 groups in the lysine 
residue. Their antimicrobial activity and hemolytic activity were obtained and listed in Table 3.1. 
Surprisingly, containing just one γ-AApeptide building block and one lysine residue, 1 
show potent activity against both Gram-positive and Gram-negative bacteria. More importantly, 
it is highly selective to bacteria because it does not exhibit discernable hemolytic activity up to 
200 µg/mL, and HC50 is even more than 500 µg/mL. It is much superior to drug candidate 
pexiganan, the analog of HDP Magainin, in terms of both activity as well as the hemolytic 
activity. It also possess better selectivity than previously developed lead lipo-γ-AApeptide γ6. In 
addition, while γ6 is much longer and a few more steps are needed for the synthesis, 1 can be 
generated much faster. The result demonstrates that α/γ-AA hybrid peptides are a class of 
promising antibiotic agents. Similar to other classes of antimicrobial peptidomimetics, the 
33 
 
antimicrobial activity and hemolytic activity can be tuned via the manipulation of hydrophobicity 
and hydrophobicity. For example, the selectivity of α/γ-AA hybrid peptide 1 can be further 
enhanced after another hydrophilic γ-AApeptide building block is included, and this led to the 
identification of chimeric peptide 3. As shown in Table 3.1, with decreased ratio of 
hydrophobicity/hydrophobicity, 3 does not show any hemolytic activity even up to 350 µg/mL, 
while its antimicrobial activity is still comparable to 1. Increase in the hydrophobicity also 
enhances antimicrobial activity, and this has been observed for 5, 7, 9, and 11, which contains 
one or two amphiphilic γ-AApeptide building blocks, exhibiting more potent and broad-spectrum 
activity than 1 and 3. It seems both aromatic phenyl group and aliphatic isopropyl group induce 
similar hydrophobicity as these sequences have almost identical antimicrobial activity.  
However, it is also consistent to the general understanding that increased hydrophobicity lead to 
increased hemolytic activity, thus compromising the selectivity. As the matter of fact, 5, 7, 9, and 
11 are all much more hemolytic than 1 and 3. 
Interestingly, most hybrid peptides containing two C16 alkyl tails are not active against 
any bacteria.  For instance, peptides 2 and 4 are di-alkyl version of 1 and 3, however, they 
completely abolish their antimicrobial activity. The same phenomena have also been observed 
for peptides 6, 8 and 12. Although 10 displays good activity against a few bacterial strains, 
however, its activity is still not as broad-spectrum as mono-alkylated peptides. The results seem 
counter-intuitive, since di-alkylation significantly increases the overall hydrophobicity of 
molecules, and as such, the interaction between hybrid peptides and bacterial membranes are 
expected to much stronger. However, we believe it is possible due the following reason. 
Although the mode of action of HDPs is still elusive, it is wide accepted that certain orientations 
of peptides are required on the surface of bacteria so as to maximize their interactions with 
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bacteria membranes.2,23 Since tails are very hydrophobic in di-alkylated hybrid peptides, it is 
highly possible that they form stable micelle structure in aqueous environment. The hydrophobic 
interaction is so strong and the micelles do not dissociate on the surface of bacterial membranes. 
As the result, the peptides do not or only weakly penetrate the membranes of bacteria. We 
believe this result may shed light on the design of future lipo-peptidic antimicrobial agents. 
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Figure 3.2 The structures of lipidated α/γ-AA chimeric peptides. γ6 is a previously prepared 
lipidated γ-AApeptide which is included for comparison. 18 
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Table 3.1 The antimicrobial and hemolytic activities of lipidated cyclic γ-AApeptides. The 
microbial organisms used are E. coli (ATCC 25922), P. aeruginosa (ATCC 27853), Methicillin-
resistant S. epidermidis (RP62A), Vancomycin-resistant E. faecalis (ATCC 700802), and 
Methicillin-resistant S. aureus (ATCC 33591). The minimum inhibitory concentration (MIC) is 
the lowest concentration that completely inhibits growth after 24 h. HC10/HC50 is the 
concentration causing10% and 50% hemolysis, respectively. Pexiganan24,25 and previously 
reported lipidated γ-AApeptide γ6 18 are included for comparison.  
 
Sequences MRSA 
(+) 
(µg/mL) 
MRSE 
(+) 
(µg/mL) 
E. Faecalis 
(+)  
(µg/mL) 
P. Aeruginosa 
(-)        
(µg/mL) 
E. Coli (-) 
(µg/mL) 
Hemolysis 
(HC10/ HC50) 
(µg/mL) 
1 4 4 5 2 5 200/>500 
2 >50 >50 >50 >50 >50 ----- 
3 4 2 4 2 3 350/>500 
4 >50 >50 >50 >50 >50 ----- 
5 2 2 2 2 4 40/150 
6 >50 >50 >50 >50 >50 ----- 
7 2 2 2 2 4 40/250 
8 >50 >50 >50 >50 >50 ----- 
9 2 2 2 2 2 30/100 
10 2 2 2 3 25-50 50/400 
11 2 2 2 2 4 45/350 
12 >50 >50 >50 >50 >50 ----- 
γ6 4 4 5 5 3 60/500 
Pexiganan 16 8 32 16 8 --/120 
 
 
 
Figure 3.3 Time-kill curves for MRSA (a) and E. Coli (b). The killing activity of α/γ-AA hybrid 
peptide 3 against those strains was monitored for the first 2 h. 
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As these lipo-α/γ-AA hybrid peptides were designed to mimic the function of HDPs, their 
bactericidal action should result from irreversible disruption of bacterial membranes.25 In 
addition, there are expected to exert their antibacterial activity rapidly. As such, the kinetics of 
bacterial killing of the lipo-α/γ-AA hybrid peptide 3 against both Gram-positive bacteria MRSA 
and Gram-negative bacteria E. coli were investigated.  The concentrations were tested at 3 ×, 6 
×, and 12 × the MIC, and cell viability within the first 2 h were determined by colony count in 
agar plates. As shown in Figure 3.3, for both MRSA and E. coli, the rate of bacterial killing was 
dependent on the concentration of 3. In 2 h, 3 at concentrations of both 25 µg/mL and 50 µg/mL 
could completely eradicate bacteria greater than 105 CFU/mL. At highest concentration 50 
µg/mL, 3 killed both bacteria completely in just one hour. The data also suggest that E. coli is 
more sensitive to 3 for killing than MRSA, since 25 µg/mL of 3 already completely eradiated E. 
coli in 1 h, and at 12.5 µg/mL of 3 reduced 99.9% E. coli. Overall, these results show that 3 exert 
its bactericidal activity rapidly. Similar to other reported HDP analogues, 25 the bactericidal 
action of 3 is concentration dependent against the strains of bacteria which were exposed. 
Based on the broad-spectrum antimicrobial activity and high selectivity of these short 
lipo-α/γ-AA hybrid peptides, their ability of rapid killing of bacteria, as well as their cationic 
amphipathic structures, we hypothesize that they could mimic the mode of action of HDPs, and 
kill bacterial pathogens via membrane disruption. As such, a fluorescence microscopy 
experiment was carried out to study the impact of the lead peptide 3 to affect the membranes of 
S. aureus (Gram-positive bacterium) and E. coli (Gram-negative bacterium). Both bacteria were 
stained with dyes 4',6-diamidino-2-phenylindole (DAPI) and propidium iodide (PI) (Figure 3.4). 
DAPI is a membrane permeable dye which can cross membranes irrelevant of cell viability, 
however, PI can only stain cells when cell membranes are damaged. As shown in Figure 3.4, 
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treatment of bacteria with peptide 3 resulted in visibility of red-fluorescent bacteria under PI 
channel, suggesting the membranes of both S. aureus and E. coli were damaged.  Consistent to 
our previous results and findings from other groups, treatment with 3 led to significant 
aggregation of S. aureus, which is believed to arise from the dissipation of membrane potential 
due to membrane disruption.1,16-19,26-28 
 
Figure 3.4 Fluorescence micrographs of S. aureus (A) and E. coli (B) that are treated or not 
treated with 5 µg/mL lipidated α/γ-AA peptide 3 for 2 h.  a1, control, no treatment, DAPI 
stained; a2, control, no treatment, PI stained; a3, control, no treatment, merged. b1, treatment 
with 3, DAPI stained; b2, treatment with 3, PI stained; b3, treatment with 3, merged. 
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3.3 Conclusions 
In summary, we have developed and identified short lipo-α/γ-AA hybrid peptides that 
display potent and broad-spectrum activity against medicinally relevant Gram-positive and 
Gram-negative bacteria. Compared to previously developed lipo-γ-AApeptides, these short lipo-
α/γ-AA chimeric peptides are comparable active. However, this class of hybrid peptides are 
easier to access in large quantity, and the lead compounds are even more selective to bacteria and 
almost do not show any hemolytic toxicity under the tested conditions. They mimic HDPs by 
rapidly permeating and damaging bacterial membranes, and kill bacteria in a short period of 
time. Due to their simplicity and high selectivity, lipo- α/γ-AA chimeric peptides may have great 
potential to be developed into a new class of antibiotic agents to combat drug-resistance. 
3.4 Experimental Section 
3.4.1 General experimental methods 
Rink amide MBHA resins (200-400 mesh, 0.7 mmol/g) were ordered from Chem-Impex 
Int’l Inc. Other chemicals were obtained from either Sigma-Aldrich or Fisher Scientific. The 
short antimicrobial lipo-AA peptides were synthesized in a peptide reaction vessel on a Burrell 
Wrist-Action shaker, then analyzed and purified with a Waters HPLC system containing both 
analytical and preparative functions. HPLC fractions were collected and confirmed using a 
Bruker AutoFlex MALDI-TOF mass spectrometer. The final products were dried in a Labcono 
lyophilizer. 
3.4.2 Solid phase synthesis, purification and characterization of short lipo-AApeptides 
 Figure 3.5 shows the structures of the building blocks used to synthesize short lipo-
AApeptides. The syntheses of the first three building blocks followed a previously reported 
procedure19,29-32 , Nα-Fmoc-Nε-Boc-L-lysine and palmitic acid were purchased. 
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Figure 3.5 Building blocks used to synthesize lipo-AApeptides. 
 
The assemblies of the AApeptides sequences are based on building blocks strategy 
adopting Fmoc chemistry. For every coupling step, 20% Piperidine in DMF was first used to 
remove the Fmoc protecting group, then 1.5 equivalent of building blocks/ Nα-Fmoc-Nε-Boc-L-
lysine with 4 equivalent of HOBT (1-hydroxybenzotriazole monohydrate) and DIC 
(diisopropylcarbodiimide) were added using DMF as solvents to react for 4 hours. The last 
coupling was using palmitic acid instead of building blocks/ Nα-Fmoc-Nε-Boc-L-lysine. The 
short lipo-AApeptides were cleaved from the amide resin in 50:48:2 TFA/DCM/TIS 
(triisopropylsilane) for 2 hours. The solvents were air-blowed overnight, and the peptide 
sequences were analyzed and purified on a Waters HPLC system monitored at 215 nm. The 
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potential fractions were collected and confirmed by Bruker AutoFlex MALDI-TOF mass 
spectrometer before they were lyophilized. The MALDI results are shown in Table 3.2. 
Table 3.2 MALDI analysis of lipo-AApeptides 
Short Lipo-AApeptides Molecular Weight (Actual) Molecular Weight (observed) 
1 639.541 640.608 (M+H+) 
2 877.771 878.811 (M+H+) 
3 895.731 895.845 (M+H+) 
4 1133.961 1135.236(M+H+) 
5 658.515 659.671(M+H+) 
6 896.744 897.893 (M+H+) 
7 933.678 934.926 (M+H+) 
8 1171.908 1173.241(M+H+) 
9 624.530 624.732(M+H+) 
10 862.760 863.471(M+H+) 
11 865.709 866.819 (M+H+) 
12 1103.939 1104.971 (M+H+) 
 
3.4.3 Antimicrobial assays 
To determine the antimicrobial activities of these lipo-AApeptides, MICs (Minimal 
Inhibitory Concentrations) were measured against five different bacteria strains like Methicillin-
resistant S. aureus (MRSA, ATCC 33592), Methicillin-resistant S. epidermidis (MRSE, RP62A), 
Vancomycin-resisitant E. faecalis (ATCC700802), multi-drug resistant P. aeruginosa 
(ATCC27853), and E.coli (ATCC 25922). The highest drug concentration used was 50 ug/ml. 
First, a single colony of each bacteria strain was inoculated into 5 ml of Tryptic Soy Broth (TSB) 
medium to grow to the mid-logarithmic phase, and then the bacteria culture was diluted to 
1x10^6 CFU/ml suspension. Aliquots of 50 ul of these bacteria suspension were added into 50 ul 
of different concentrations of lipo-AApeptides diluted using the same TSB medium. The 
mixtures were incubated at 370C for 12-16 hours, and the cell growth was monitored by a Biotek 
Synergy HT microtiter plate reader at 600 nm wavelength. MICs are the lowest concentrations of 
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the compounds which can inhibit the bacteria growth. Results were repeated multiple times with 
duplicates each time. 
3.4.4 Hemolysis assays 
Wash the freshly drawn, K2EDTA treated human red blood cells (hRBCs) with PBS 
buffer, and centrifuge at 1000g for 10 min. Repeat several times until the supernatant is clear. 
Take out the clear supernatant, dilute the RBCs into 5% v/v suspension, and mix with serial 
diluted lipo-AApeptides in a 96-well plate. The mixtures were incubated at 370C for 1 hour and 
then centrifuged at 3500 rpm for 10 min. Transfer 30 ul of the supernatant into 100 ul PBS, and 
read the absorbance at 360 nm using a Biotek Synergy TH plate reader. % hemolysis = 
(Abssample-AbsPBS)/(AbsTriton-AbsPBS)x100%. Negative controls were done by mixing blood with 
PBS, and positive controls were determined by mixing blood with Triton X-100. The results 
were repeated several times with duplicates for each time. 
3.4.5 Fluorescence microscopy 
Fluorescence microscopy is to test the bacterial membrane integrity by using two dyes: 
DAPI (4’,6-diamidino-2-phenylindole dihydrochloride) and PI (propidium iodide) to stain E.coli 
and MRSA. PI can only pass through damaged membranes therefore it can only stain dead cells; 
however DAPI can dye all the bacterial cells regardless of the viabilities. Grow the bacteria to 
mid-logarithmic phase and incubate them with lipo-AApeptides (YL-64 as an example) at 2 X 
MIC for 2 hours. The culture was then centrifuged at 5000g for 15 min. The pellets after 
centrifuge were washed with PBS then incubated with PI (5ug/ml), followed by PBS washing 
and DAPI (10ug/ml) incubation. Each dye incubation was 15 min on ice in dark. Controls were 
bacteria without AApeptides treatment, and went through the same procedure described above. 
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The stained bacteria were observed under Zeiss Axio Image Zloptical microscope using 100X 
oil-immersion objective. 
3.4.6 Time kill kinetics of bacteria killing for 3 against MRSA and E.coli8  
Grow MRSA and E.coli to mid-logarithmic phase and dilute them into 106 CFU/ml 
suspensions. Incubate the diluted bacteria suspension with different concentrations of lipo-
AApeptides (16xMIC, 8xMIC and 4xMIC) for 10 min, 30 min, 1h and 2h respectively. After the 
incubation, dilute the mixture 102 to 104 times to spread on the TSB agar plates. Count the single 
colonies after overnight incubation at 37 0C. Graph the compound-bacteria incubation time and 
colonies log numbers to get the kinetics of lipo-AApeptides killing bacteria. 
3.5 References 
 (1) Niu, Y.; Wang, R. E.; Wu, H.; Cai, J. Future Med Chem 2012, 4, 1853. 
 (2) Hancock, R. E.; Sahl, H. G. Nature biotechnology 2006, 24, 1551. 
 (3) Marr, A. K.; Gooderham, W. J.; Hancock, R. E. Current opinion in pharmacology 
2006, 6, 468. 
 (4) Niu, Y.; Wu, H.; Li, Y.; Hu, Y.; Padhee, S.; Li, Q.; Cao, C.; Cai, J. Org. Biomol. 
Chem. 2013, 11, 4283. 
 (5) Kapoor, R.; Wadman, M. W.; Dohm, M. T.; Czyzewski, A. M.; Spormann, A. M.; 
Barron, A. E. Antimicrob Agents Chemother 2011, 55, 3054. 
 (6) Porter, E. A.; Weisblum, B.; Gellman, S. H. Journal of the American Chemical 
Society 2002, 124, 7324. 
 (7) Olsen, C. A.; Ziegler, H. L.; Nielsen, H. M.; Frimodt-Moller, N.; Jaroszewski, J. 
W.; Franzyk, H. Chembiochem 2010, 11, 1356. 
 (8) Choi, S.; Isaacs, A.; Clements, D.; Liu, D.; Kim, H.; Scott, R. W.; Winkler, J. D.; 
DeGrado, W. F. Proceedings of the National Academy of Sciences of the United States of America 
2009, 106, 6968. 
 (9) Ghosh, C.; Manjunath, G. B.; Akkapeddi, P.; Yarlagadda, V.; Hoque, J.; Uppu, D. 
S.; Konai, M. M.; Haldar, J. Journal of medicinal chemistry 2014, 57, 1428. 
 
43 
 
 (10) Bremner, J. B.; Keller, P. A.; Pyne, S. G.; Boyle, T. P.; Brkic, Z.; David, D. M.; 
Garas, A.; Morgan, J.; Robertson, M.; Somphol, K.; Miller, M. H.; Howe, A. S.; Ambrose, P.; 
Bhavnani, S.; Fritsche, T. R.; Biedenbach, D. J.; Jones, R. N.; Buckheit, R. W.; Watson, K. M.; 
Baylis, D.; Coates, J. A.; Deadman, J.; Jeevarajah, D.; McCracken, A.; Rhodes, D. I. Angewandte 
Chemie International Edition 2010, 49, 537. 
 (11) Niu, Y.; Hu, Y.; Li, X.; Chen, J.; Cai, J. New Journal of Chemistry 2011, 35, 542. 
 (12) Wu, H.; Li, Y.; Ge, B.; Niu, Y.; Qiao, Q.; Tipton, J.; Cao, C.; Cai, J. Chemical 
Communications 2014, DOI: 10.1039/C3CC46685J  
 (13) Yang, Y.; Niu, Y.; Hong, H.; Wu, H.; Zhang, Y.; Engle, J.; Barnhart, T.; Cai, J.; 
Cai, W. Chemical Communications 2012, 48, 7850. 
 (14) Niu, Y.; Bai, G.; Wu, H.; Wang, R. E.; Qiao, Q.; Padhee, S.; Buzzeo, R.; Cao, C.; 
Cai, J. Molecular pharmaceutics 2012, 9, 1529. 
 (15) Niu, Y.; Jones, A. J.; Wu, H.; Varani, G.; Cai, J. Org Biomol Chem 2011, 9, 6604. 
 (16) Wu, H.; Niu, Y.; Padhee, S.; Wang, R. E.; Li, Y.; Qiao, Q.; Ge, B.; Cao, C.; Cai, J. 
Chem. Sci. 2012, 3 2570. 
 (17) Niu, Y.; Padhee, S.; Wu, H.; Bai, G.; Harrington, L.; Burda, W. N.; Shaw, L. N.; 
Cao, C.; Cai, J. Chemical communications (Cambridge, England) 2011, 47, 12197. 
 (18) Niu, Y.; Padhee, S.; Wu, H.; Bai, G.; Qiao, Q.; Hu, Y.; Harrington, L.; Burda, W. 
N.; Shaw, L. N.; Cao, C.; Cai, J. Journal of medicinal chemistry 2012, 55, 4003. 
 (19) Li, Y.; Smith, C.; Wu, H.; Padhee, S.; Manoj, N.; Cardiello, J.; Qiao, Q.; Cao, C.; 
Yin, H.; Cai, J. ACS Chem Biol 2014, 9, 211. 
 (20) Makovitzki, A.; Avrahami, D.; Shai, Y. Proceedings of the National Academy of 
Sciences of the United States of America 2006, 103, 15997. 
 (21) Chongsiriwatana, N. P.; Miller, T. M.; Wetzler, M.; Vakulenko, S.; Karlsson, A. J.; 
Palecek, S. P.; Mobashery, S.; Barron, A. E. Antimicrob Agents Chemother 2011, 55, 417. 
 (22) Schmitt, M. A.; Weisblum, B.; Gellman, S. H. Journal of the American Chemical 
Society 2004, 126, 6848. 
 (23) Hancock, R. E. W.; Brown, K. L.; Mookherjee, N. Immunobiology 2006, 211, 315. 
 (24) Thaker, H. D.; Som, A.; Ayaz, F.; Lui, D. H.; Pan, W. X.; Scott, R. W.; Anguita, 
J.; Tew, G. N. Journal of the American Chemical Society 2012, 134, 11088. 
 (25) Ge, Y.; MacDonald, D. L.; Holroyd, K. J.; Thornsberry, C.; Wexler, H.; Zasloff, 
M. Antimicrob Agents Chemother 1999, 43, 782. 
44 
 
 (26) Padhee, S.; Hu, Y.; Niu, Y.; Bai, G.; Wu, H.; Costanza, F.; West, L.; Harrington, 
L.; Shaw, L. N.; Cao, C.; Cai, J. Chemical communications (Cambridge, England) 2011, 47, 9729. 
 (27) Hu, Y.; Amin, M. N.; Padhee, S.; Wang, R.; Qiao, Q.; Ge, B.; Li, Y.; Mathew, A.; 
Cao, C.; Cai, J. ACS Med. Chem. Lett 2012, 3, 683. 
 (28) Padhee, S.; Smith, C.; Wu, H.; Li, Y.; Manoj, N.; Qiao, Q.; Khan, Z.; Cao, C.; Yin, 
H.; Cai, J. Chembiochem 2014. 
 (29) Hu, Y. G.; Li, X. L.; Sebti, S. M.; Chen, J. D.; Cai, J. F. Bioorg Med Chem Lett 
2011, 21, 1469. 
 (30) Niu, Y. H.; Padhee, S.; Wu, H. F.; Bai, G.; Harrington, L.; Burda, W. N.; Shaw, L. 
N.; Cao, C. H.; Cai, J. F. Chem Commun 2011, 47, 12197. 
 (31) Niu, Y. H.; Hu, Y. G.; Li, X. L.; Chen, J. D.; Cai, J. F. New J Chem 2011, 35, 542. 
 (32) Padhee, S.; Hu, Y. G.; Niu, Y. H.; Bai, G.; Wu, H. F.; Costanza, F.; West, L.; 
Harrington, L.; Shaw, L. N.; Cao, C. H.; Cai, J. F. Chem Commun 2011, 47, 9729. 
 
45 
 
 
 
 
 
 
CHAPTER 4: HELICAL ANTIMICROBIAL SULFONO-γ-AAPEPTIDES 
 
 
Note to Reader 
Contents in this chapter have been previously published in J. Med. Chem., 2015, 58(11), 
4802-4811 and have been reproduced with the permission of the American Chemical Society. 
4.1 Introduction 
The emerging antibiotic resistance poses an increasing threat to global public health. 1 
The resistance developed by multidrug-resistant pathogens including E. coli, P. aeruginosa, S. 
aureus, and S. epidermidis have been recognized by World Health Organization (WHO) as one 
of the biggest threats in the 21st century.2 Thus, it is considerably significant to develop the new 
generation of antibiotics combating drug resistance more effectively. Natural cationic host-
defense peptides (HDPs) have attracted substantial interest because they are believed to have 
lower risk of resistance.3,4 Although HDPs are highly diverse in secondary structure, including α-
helices, β-sheets, and extended conformations, 3 they share common features being cationic and 
amphipathic, i.e. one face has hydrophobic clusters and the other face is cationic, 5 which allows 
them to interact with bacterial membranes effectively and selectively. This is because bacterial 
cell membranes contain predominantly negatively charged phospholipids including cardiolipin 
and phosphatidylglycerol, 6 which gives rise to a favorable electrostatic attraction to cationic 
HDPs. In addition, bacterial cell walls are also rich in acidic molecules, e.g., teichoic acids in the 
peptidoglycan layer of Gram-positive bacteria and lipopolysaccharides in the outer membranes 
of Gram-negative bacteria. However, the surface of eukaryotic cell membranes are composed of 
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zwitterionic phospholipids such as phosphatidylcholine, cholesterol and sphingomyelin, and 
negatively charged phospholipids are mainly sequestered in the inner leaflets of plasma 
membranes.7 The difference in the surface charge of bacteria and mammalian cells may have 
accounted for the selectivity of HDPs. 5 Upon association with bacterial membranes, HDPs, 
whether structured or random-coiled in solution, adopt ordered amphipathic conformations, and 
utilize their hydrophobic domains to penetrate lipid bilayer, leading to membrane thinning, 
disruption and subsequent cell death.5,8 Even for certain HDPs which have intracellular targets, 
interactions with bacterial membranes are critical for the cellular entry of peptides. 6 Although no 
therapeutic agents can be devoid of resistance development, HDPs may possess minimal 
probability, because the membrane disruption by HDPs is rather biophysical and lack specific 
membrane targets, making it difficult for bacteria to induce resistance. 9,10  
Despite the promise as novel agents to combat antibiotic resistance, HDPs possess 
intrinsic drawbacks, such as susceptibility to proteolytic degradation and low-to-moderate 
activity. For example, magainin 2 is a natural cationic HDP11 that shows broad-spectrum yet 
moderate antimicrobial activity. Many synthetic analogs have been developed to improve the 
activity and efficacy, and one of the success is Pexiganan (also known as MSI-78) which was in 
clinical trials for diabetic foot ulcers. Similar to magainin 2, Pexiganan is unstructured in 
solution. However, it adopts antiparallel dimer of amphipathic helices upon binding to bacterial 
membranes, leading to membrane disruption. 12 Gellman et al successfully obtained the crystal 
structure of the dimer of a magainin 2 analogue, suggesting this type of structural arrangement 
may be universal in magainin 2 and its derivatives.13 However, Pexiganan failed in phase III 
clinical trials for ulcer treatment, largely due to its moderate antimicrobial activity and low in 
vivo stability. 12 
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To develop new generations of antibiotic agents with minimal probability for resistance 
selection, yet enhanced activity and stability, an alternative approach is to develop unnatural 
peptidomimetics that mimic the helical amphipathic structure and mechanism of action of 
magainin 2. However, to date only a few classes of helical peptidomimetics have been designed 
to mimic magainin 2, such as β-peptides, 14-16 peptoids, 17 and oligoureas.18  
Recently, we developed a new class of unnatural helical foldamer termed “sulfono-γ-
AApeptides”, as they are oligomers of N-sulfono-acylated-N-aminoethyl amino acids (Figure 
4.1). 19 Our previous studies showed that sulfono-γ-AApeptides form stable helical structures in 
solution with helical pitch and diameter akin to those of α-helix.19 Thus, sulfono-γ-AApeptides 
may become a new class of promising peptidomimetics to mimic the structure and function of 
helical peptides. However, they may be more advantageous than α-helical peptides for biological 
applications because the unnatural backbone of the sulfono-γ-AApeptides could make them more 
resistant to proteolytic degradation, and amendable for enormous chemical diversification.19-22 
We have previously developed regular AApeptides to mimic global amphipathic structures of 
HDPs,1,23-27 however, those sequences were designed to form extended, more or less random 
structures, rather than helical structures when interacting with bacterial membranes. Therefore, 
we believe it is compelling to explore helical sulfono-γ-AApeptides for their ability to mimic 
magainin-2, which may provide insight into the design of a new generation of antibiotic agents. 
4.2 Results and Discussion 
Our recent X-ray crystallography and 2D-NMR analysis have suggested that the sulfono-
γ-AApeptide containing eight sulfono-γ-AA building blocks (comparable to a 16-mer peptide in 
length) adopts a well-defined helical structure in solution (Figure 4.2).19 Indeed, the folding 
propensity of this class of peptidomimetics is considerably high since strong helicity is exhibited 
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in the sequence containing just five building blocks  (comparable to a 10-mer peptide in 
length).19 In addition, the special distribution of side chains on the helical scaffold reveals that 
each helical turn consists of four side chains, similar to the parameter of 3.6 residues/turn 
existing in the α-helix (Figure 4.2).19 
 
 
Figure 4.1 The general chemical structures of α-peptides and sulfono-γ-AApeptides. 
 
 
 
Figure 4.2 The schematic representation of a helical sulfono-γ-AApeptide containing eight 
sulfono-γ-AA building blocks. A and B denote the chiral side chain and the sulfonamido side 
chain from the building blocks respectively. 
 
Based on the abovementioned structural model, we set out to design a series of sulfono-γ-
AApeptides with distinct amphipathicity, length, and hydrophobicity, in order to understand the 
structure-function relationship existing in this class of foldamer for antimicrobial application 
(Figure 4.3). These sulfono-γ-AApeptides were synthesized following our previous protocol on 
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the solid phase. 19 Among them, sequences 1 through 7 were designed based on the previously 
published NMR structure of an 8-mer sulfono-γ-AApeptide. 19 These sequences comprise of 
different distributions of cationic ammonium groups and hydrophobic phenyl groups. Sequences 
8-12 contain same side chains as 1-7, however, with shorter lengths. To assess the impact of 
function groups on the antimicrobial activity, sequences 13-15, containing hydrophobic 
isopropyl functional groups instead of aromatic groups found in other sequences, were also 
synthesized. In order to better understand the charge distribution and amphipathicity of the 
sequences, they are schematically shown on the helical scaffold in Figure 4.3. These sequences 
were then tested for their antimicrobial activity against a range of multidrug-resistant Gram-
positive and Gram-negative bacterial pathogens. Their toxicity towards either blood cells or 
other mammalian cells was also investigated (Table 4.1). 
As expected, some helical sulfono-γ-AApeptides display very potent and broad-spectrum 
antimicrobial activity against a panel of both Gram-positive and -negative multidrug-resistant 
bacterial strains. Additionally, excellent structure-activity relationship exists in the studied 
sequences. Sequences 1 and 2, containing alternative cationic and hydrophobic groups, show no 
or only negligible activity towards all bacteria, indicating amphipathicity is important to 
antimicrobial activity. In contrast, sequence 3 comprises of alternative hydrophobic and cationic 
building blocks, thus it possess same number of charges and hydrophobic groups as 1 and 2. 
However, it exhibits much enhanced antimicrobial activity, possibly due to its amphipathic 
helical structure, which facilitates its interaction with bacterial membranes. As expected, 
replacement of two cationic charges with hydrophobic groups in 3 lead to sequence 4 and 5 with 
further improved broad-spectrum activity, owing to stronger hydrophobic interaction with 
bacterial lipid layers.25,28,29 Interestingly, compared with 4, sequence 5 only lacks an acetyl group 
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on the N-terminus; however, it displays slightly better antimicrobial activity and considerably 
less hemolytic activity. 
 
Table 4.1 The antimicrobial and hemolytic activities of sulfono-γ-AA peptides. The microbial 
organisms used are E. coli (ATCC 25922), P. aeruginosa (ATCC 27853), Methicillin-resistant S. 
epidermidis (MRSE) (RP62A), Vancomycin-resistant E. faecalis (ATCC 700802), and 
Methicillin-resistant S. aureus (MRSA) (ATCC 33591). The minimum inhibitory concentration 
(MIC) is the lowest concentration that completely inhibits microbial growth after 24 h. HC50 is 
the concentration causing 50% hemolysis. Hemolysis activity was not measured for 
peptidomimetics that did not exhibit antimicrobial activity. Cytotoxicity of 6 and 7 was measured 
against N2APP cells. Pexiganan 30,31 is included for comparison. 
 
Sequence
s 
MIC ((µg/mL) Hemolysi
s (HC50, 
µg/mL) 
Cytotoxicit
y N2APP 
(EC50, 
µg/mL)  
MRSA 
(Gram+
)  
MRSE 
(Gram+
) 
E. 
faecalis 
(Gram+) 
P. 
Aeruginosa 
(Gram-)        
E. coli 
(Gram-
) 
1 >50 >50 >50 >50 >50 --------  
2 25 6 50 >50 >50 >250  
3 12 4 6 >50 6 150  
4 5 2 10 20 3 80  
5 3 2 10 15 3 120  
6 4 2 2 6 4 75 80 
7 2 2 2 4 4 100 >100 
8 >50 >50 >50 >50 >50 ----------  
9 >50 20 >50 >50 25 >250  
10 >50 20 >50 >50 25 >250  
11 6 3 >50 25 12 >250  
12 3 3 >50 12 12 >250  
13 >50 >50 >50 >50 >50 --------  
14 >50 12 >50 50 25 >250  
15 >50 12 >50 50 12 >250  
Pexigana
n 
16 8 32 16 8 120  
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Figure 4.3A Chemical structures of sulfono-γ-AApeptides (1-7). 
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Figure 4.3B Chemical structures of sulfono-γ-AApeptides (8-15). 
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Figure 4.3C Structures of antimicrobial sulfono-γ-AApeptides and their charge (blue dots) 
distribution on the helical scaffold. Although sequences 8 and 9 are not expected to form helical 
structures due to their short length, they are shown on the helical scaffold just for comparison to 
other sequences. 
 
We next asked if the same charge/hydrophobicity distribution but different location on 
the helical scaffold affects antimicrobial activity or not, thus 6 and 7 were synthesized. In 
comparison to 4 and 5, sequences 6 and 7 have cationic charges on the other face of helical 
scaffold (Figure 4.3). Intriguingly, both 6 and 7 possess further enhanced antimicrobial activity, 
which is much more potent than Pexiganan, thus stand out themselves amongst the best 
antibacterial helical peptidomimetics reported to date.14-18,32 The reason might be that the 
distances between two adjacent side chains are not always the same on the sulfono-γ-AApeptide 
helical scaffold as those in α-helix. Therefore, shift of cationic and hydrophobic patches may 
result in altered interactions with bacterial membranes. Nonetheless, the findings will be useful 
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to further develop antimicrobial sulfono-γ-AApeptides. Again, similar to 5, sequence 7 also lacks 
the acetyl group found in 6, and shows slightly better antimicrobial activity and less hemolytic 
activity. Moreover, 7 also exhibits less cytotoxicity towards mammalian cells compared to 6.  
Akin to previous findings,25,33 antimicrobial activities of sequences are dependent on their 
lengths. The shortest sequence 8 doesn’t show any activity, while when the lengths of sequences 
become longer, the activities increase accordingly. We believe there are two aspects which may 
be accounted for the results. First, our previous studies showed that sulfono-γ-AApeptides only 
form discernible helical structures when they contain five or more sulfono-γ-AApeptide building 
blocks. As such, shorter sequences including 8 and 9 may not adopt helical structures in solution, 
and therefore their structures are not amphipathic (they are illustrated on helical scaffolds in 
Figure 4.3 just for comparison). Additionally, the number of both cationic charges and 
hydrophobic groups are critical for antimicrobial activity of HDPs and their derivatives. With 
minimum number of hydrophilicity and hydrophobicity, sequences cannot selectively bind and 
interact with bacterial membranes. HDPs usually require > +5 charges for good activity. 3 
In addition to amphipathicity, it should be noted that the nature of hydrophobic groups also plays 
a very important role in the activity. Sequences of 14 and 15, containing isopropyl groups rather 
than phenyl groups found in 6 and 7, largely abolish their antimicrobial activity. This is 
reasonable, as the isopropyl group is less hydrophobic than the aromatic phenyl moiety, thus the 
sequences could not have strong interactions with bacterial membranes. 
In order to provide insight into the structure-function relationship of helical sulfono-γ-
AApeptides, we carried out SAXS (Small-Angle X-ray Scattering) studies to analyze the 
solution structures of a few lead sulfono-γ-AApeptides. SAXS become a unique tool for the 
quick assessment of the solution structures of peptides or peptidomimetics.34,35 It is particularly 
55 
 
valuable for helical sulfono-γ-AApeptides, because as a new class of peptidomimetics with 
backbone different from regular peptides, CD (circular dichroism) may not be able to interpret 
their solution structures undoubtedly.36 In particular, Kratky plot was used to assess the folding 
state of sulfono-γ-AApeptides. Bell-shape Krakty profile suggests a globular folding of proteins, 
while a plateau in middle q range suggests a random coiled folding (Figure 4.10).34,35 Figure 4.4a 
indicates that the most active sequences 6 and 7 both form helical structures in solution. The 
helicity of 6 is better than 7, suggesting acetylation of N-terminus of the sequence significantly 
impact the folding of the sequence. It is also consistent to the findings that strong-helix-forming 
antimicrobial sequences may be more hemolytic and slightly less active.25,37 Sequences with 
certain flexibility may possess optimal antimicrobial activity and selectivity.16 The other two 
active sequences 4 and 5 (Figure 4.4b) also show characteristic helical folding signatures with 
peaks around 0.1 Å-1 and the non-plateau feature in q range of 0.2-0.4 Å-1. Consistent to 
observation for 6 and 7, N-acetyl capped sequence 4 still exhibits higher helical propensity in 
comparison to 5. Interestingly, sequences 1 and 2, containing alternative cationic and 
hydrophobic residues, exhibit random-coiled feature rather than the helical bell shape in the plot. 
It may suggest that highly dense positive charges destabilize the helical folding, and therefore the 
compounds cannot form amphipathic structures when interacting with bacterial membranes. 
Consequently, they are not active at all (Table 4.1). 
Our antimicrobial and structural studies suggest that sulfono-γ-AApeptides mimic 
magainin in structure and function, therefore we hypothesized that they could also mimic 
magainin by causing membrane disruption to kill bacterial pathogens. As such, fluorescence 
microscopy studies were conducted to study the impact of peptide 7 on the membranes of S. 
aureus (Gram-positive bacterium) and E. coli (Gram-negative bacterium). Two dyes 4',6-
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diamidino-2-phenylindole (DAPI) and propidium iodide (PI) (Figure 4.5) were employed in the 
studies. DAPI is a membrane permeable dye capable of crossing membranes regardless of cell 
viability, however PI can only intercalate DNA and fluoresce when cell membranes are 
compromised. Treatment of bacteria with 7 gave rise to the observation of red-fluorescent 
bacteria under PI channel, indicating the membranes of both S. aureus and E. coli were 
disrupted. In addition, treatment with 7 led to significant aggregation of E. coli, probably due to 
the loss of membrane potential upon membrane damage.1,24-27,33,38,39 
 
 
Figure 4.4 Krakty plot of 1, 2, 4, 5, 6 and 7 measured in pH 7.4 PBS buffer. The peaks around 
0.1 Å-1 and non-plateau feature in q range of 0.2-0.4 Å-1 suggest the good helicity in these 
sulfono-γ-AApeptides. 
 
As these sulfono-γ-AApeptides were designed to mimic helical HDPs such as magainin, 
their bactericidal action should also result from a rapid disruption of bacterial membranes. 31 As 
such, we conducted the time kill study to investigate the efficiency of 7 to kill both the Gram-
positive bacteria MRSA and the Gram-negative bacteria E. coli. Compound 7 was tested at six, 
twelve, and twenty five times of the MIC to produce a time-dependent curve. After treatment for 
10 min, 30 min, 1 hour and two hours, cell viability was determined by colony count in agar 
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plates. In 30 min, all concentrations of 7 could completely eradicate MRSA bacterium (Figure 
4.6a). At concentrations of 25 and 50 µg/mL, 7 could eradicate E. coli completely in just one 
hour. Even at 25 µg/mL, a 105 CFU/mL reduction in bacteria was observed. These results 
suggest that 7 kills bacteria rapidly, mimicking the function of magainin. Similar to other HDP 
analogues, 31 the bactericidal action of 7 is also dependent on the concentrations exposed to 
bacteria. 
 
 
Figure 4.5 Fluorescence micrographs of S. aureus (A) and E. coli (B) that are treated or not 
treated with 10 µg/mL sulfono-γ-AApeptide 7 for 2 h.  a1, control, no treatment, DAPI stained; 
a2, control, no treatment, PI stained; a3, control, no treatment, merged. b1, treatment with 7, 
DAPI stained; b2, treatment with 7, PI stained; b3, treatment with 7, merged. Scale bar for 
MRSA is 10 μm. 
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Figure 4.6 Time-kill curves of 7 for MRSA (a) and E. coli (b), respectively. The killing activity 
against those strains was monitored for the first 2 h. The concentrations used in the experiment 
were 6 ×MIC, 12 ×MIC, and 25 ×MIC, respectively. 
 
 
Figure 4.7 Analytic HPLC traces of compound 7 and a peptide control AcVQIVYK before and 
after incubation with pronase (0.1 mg/mL) in 100 mM pH 7.8 ammonium bicarbonate buffer at 
37 °C. 
 
 One of the major drawbacks of HDPs is their susceptibility to enzyme degradation. Thus, 
the stability of sulfono-γ-AApeptides was investigated by incubating compound 7 with pronase 
(0.1 mg/mL) in 100 mM pH 7.8 ammonium bicarbonate buffer. As shown in Figure 4.7, 
compound 7 showed high stability to proteolysis with no degradation occurred after incubation 
for 18 h. However, a peptide control AcVQIVYK was completely degraded by enzyme. The 
superior enzymatic stability of compound 7 demonstrates the potential of this type of new 
antimicrobial agents as new drug candidates. 
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4.3 Conclusions 
In conclusion, we reported the first example of antimicrobial helical sulfono-γ-AApeptide 
foldamers. These sequences exhibit excellent structure-function relationship. Sequences with 
defined amphipathic features show significant antimicrobial activity. Longer sequences, 
presumably adopting more-defined helical structures, and containing more charged and 
hydrophobic groups, are more potent than shorter ones. The lead molecule displays broad-
spectrum, potent and selective activity against a range of multidrug-resistant Gram-positive and 
–negative bacterial pathogens. Time-killing studies and fluorescence microscopy suggest that the 
sequences kill both Gram-positive and Gram-negative bacteria by compromising their 
membranes, a mode of action analogous to those of HDPs. The helical structures of the 
sequences were further analyzed by Small Angle X-ray Scattering (SAXS), suggesting the 
sequence with slightly less helical propensity in solution could be more potent and selective than 
the stronger helix-forming sequences. Moreover, this class of antimicrobial agents are highly 
resistant to enzyme degradation. These results may lead to a new class of antimicrobial foldamer 
combating emerging antibiotic-resistant pathogens. 
4.4 Experimental Section 
4.4.1 General information 
All Fmoc protected α-amino acids and Rink-amide resin (0.7 mmol/g, 200-400 mesh) 
were purchased from Chem-Impex International, Inc. Unless otherwise stated, all the other 
solvents and reagents were purchased from either Sigma-Aldrich or Fisher Scientific and used 
without further purification. Solid-phase synthesis of sulfono-γ-AApeptides were conducted in a 
peptide synthesis vessel on a Burrell Wrist-Action shaker. The sulfono-γ-AApeptides were 
analyzed and purified on a Waters Breeze 2 HPLC system, and then lyophilized on a Labcono 
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lyophilizer. The molecular weight of sulfono-γ-AApeptide was obtained on an Applied 
Biosystems 4700 Proteomics Analyzer. 
4.4.2 Synthesis of sulfono-γ-AApeptides 
The syntheses of N-alloc γ-AApeptide building blocks AA1 to 3 used for sulfono-γ-
AApeptides adopted a similar method reported by our research group.40,41 
 
 
Figure 4.8 N-alloc γ-AApeptide building blocks and sulfonyl chlorides used for synthesizing 
sulfono-γ-AApeptides. 
 
Sulfonyl chloride AA5 and 6 were purchased from AK Scientific, Inc. and used without 
further purification. Sulfonyl chloride AA4 was synthesized following the previously reported 
method, 42 which is shown in Figure 4.9. 
 
Figure 4.9 The synthesis of a sulfonyl chloride AA4. 
 
The syntheses of sulfono-γ-AApeptide sequences was carried out on solid phase utilizing 
Fmoc chemistry and alloc-protected building block strategy. 100 mg of the rink amide resin (0.7 
mmol/g) was mixing with 20% piperidine in DMF to remove the Fmoc protecting group. Then 
61 
 
the resin was washed with DCM (x3) and DMF (x3). A premixed solution of N-alloc γ-
AApeptide building block (2 equiv.), HOBt (4 equiv.), and DIC (4 equiv.) in 2 mL DMF was 
added to the resin. The mixture was shaken for 4 h. After being washed with DCM and DMF, the 
resin was treated with Pd(PPh3)4 (8 mg, 0.007 mmol) and Me2NH·BH3 (25 mg, 0.42 mmol) in 3 
mL DCM for 10 min (x2), then reacted with the desired sulfonyl chloride (4 equiv.) and DIPEA 
(6 equiv.) in 3 mL DCM for 30 min (x2). The reaction cycles were repeated until the desired 
sequence was assembled on the solid phase. After that, the resin was washed with DCM and 
dried in vacuo. The cleavage of the sequences was done in the cocktail of 50% TFA, 48% DCM 
and 2% TIS for 2 hour incubation. After TFA was removed, the sulfono-γ-AApeptides were 
analyzed and prepared on Waters HPLC system monitored at 215 nm. The desired fractions with 
correct molecular weights (confirmed by MALDI-TOF) were lyophilized. The Table 4.2 below 
showed the molecular weights of our compounds confirmed by MALDI-TOF. 
 
Table 4.2 MALDI-TOF analyses of sulfono-γ-AApeptides 
 
Compound Name Exact Mass Observed (MALDI-TOF ) 
1 2660.205 2662.188 (M+H+) 
2 2435.955 2437.184 (M+H+) 
3 2548.080 2549.214 (M+H+) 
4 2642.090 2643.994 (M+H+) 
5 2600.079 2602.038 (M+H+) 
6 2586.027 2587.277 (M+H+) 
7 2544.016 2545.271 (M+H+) 
8 639.287 640.839 (M+H+) 
9 1280.521 1281.704 (M+H+) 
10 1558.663 1559.804 (M+H+) 
11 1902.782 1903.892 (M+H+) 
12 2199.897 2200.985 (M+H+) 
13 2164.080 2165.702 (M+H+) 
14 2246.183 2247.407 (M+H+) 
15 2204.173 2205.464 (M+H+) 
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4.4.3 Minimum inhibitory concentrations (MICs) against bacteria 
Five bacteria strains including Methicillin-resistant S. aureus (MRSA, ATCC 33592), 
Methicillin-resistant S. epidermidis (MRSE, RP62A), Vancomycin-resisitant E. faecalis 
(ATCC700802), P. aeruginosa (ATCC27853), and E.coli (ATCC 25922) were used to test 
antimicrobial activities of the sulfono-γ-AApeptides, Briefly, single colonies of these bacteria 
were inoculated into 3 mL TSB medium and allowed to grow overnight. Then the bacteria were 
re-inoculated at 1:100 dilution and grew to mid-logarithmic phase, before they were diluted to 1 
x 106 CFU/mL suspension. Aliquots of 50 µL of these bacteria suspension were added into 50 
µL of serial dilutions of sulfono-γ-AApeptides starting from 25 µg/mL. After incubation at 37 °C 
for 16 hours, the mixtures were read at 600 nm wavelength by a Biotek Synergy HT microtiter 
plate reader. The MICs were determined as the lowest concentration at which the bacteria cannot 
grow. Results were repeated multiple times with duplicates each time. 
4.4.4 Hemolytic assays 
The freshly drawn, K2EDTA treated human red blood cells (hRBCs) were washed with 
1X PBS buffer, and then centrifuged at 1000 g for 10 min. The step was repeated serveral times 
until the supernatant was clear. After the clear supernatant was removed, the RBCs were diluted 
into 5% v/v suspension. This RBC suspension was incubated with equal volume of sulfono-γ-
AApeptides at different concentrations at 37 °C for 1 hour. The mixture was then centrifuged at 
3500 rpm for 10 min. Next, 30 µL of the supernatant was transferred into 100 µL PBS, and the 
absorbance was read at 360 nm using a Biotek Synergy TH plate reader. The hemolysis 
percentage was calculated by the formula % hemolysis = (Abssample-AbsPBS)/(AbsTriton-
AbsPBS)x100%. Positive controls were RBCs with 2 %Triton X-100, and negative controls were 
RBCs with 1X PBS. Results were repeated at least three times with duplicates each time. 
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4.4.5 Fluorescence microscopy 
Fluorescence microscopy was used to determine the integrity of bacterial membranes. 
Two dyes 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI) and propidium iodide (PI), 
were used.DAPI is able to dye all bacteria cells regardless of their viabilities, and PI can only 
pass through damaged membranes therefore can only stain dead cells. After the bacteria grew to 
mid-logarithmic phase, they were incubated with sulfono-γ-AApeptides at 37 °C for 2 hours. The 
culture was then centrifuged at 5000 g for 15 min, and the cell pellets were collected, washed, 
and then incubated with PI (5 µg/mL) then with DAPI (10 µg/mL) for 15 min on ice. Controls 
were bacteria without AApeptides treatment. After the final wash, 10 µL of the samples were 
placed on chamber slides and observed under Zeiss Axio Image Zloptical microscope using 
100X oil-immersion objective. 
4.4.6 Time kill study 
The kinetics of sulfono-γ-AApeptides killing bacteria were studied. The bacteria MRSA 
and E.coli were let grow to mid-logarithmic phase in TSB medium, then the cultures were 
diluted into 106 CFU/ml suspensions. The diluted bacteria suspensions were incubated with 
different concentrations of sulfono-γ-AApeptides for 10 min, 30 min, 1 h and 2 h respectively. 
The mixtures were diluted into 102 to 104 times and then spread on TSB agar plates. After 
overnight incubation at 37 °C, the colonies on the plates were counted and graphed against 
compound-bacteria incubation time. 
4.4.7 MTT assay 
N2a APP cells were used to access the cell viability after treatment of 6 and 7. Typically, 
stock concentration of the drug (1 mg/mL) was diluted in media in 96-well plate to make serial 
concentrations, and then incubated at 37 ºC. In another 96-well plate, N2a APP cells were seeded 
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to 1×104 cells/well, each of which contained 100 μL media. After incubation for 12 hours, 100 
µL of drugs were added and the plate was incubated for 36 hours.. The media in 96-well plate 
was removed and washed with fresh media once, followed by adding 110 µL MTT reagent, and 
then incubation for another 4 h, after which 100 µl of pre-warmed solubilization solution was 
added. The plate was then incubated at 37 ºC for 12 h before absorbance at 550 nm was read. 
Percentage of cell viability was calculated based on the following equation: 
cell viability % = (A/Acontrol) × % 
4.4.8 Small-Angle X-ray Scattering (SAXS) experiment 
Small-angle x-ray scattering measurements were conducted at Beamline 12ID-B of 
Advanced Photon Sources (APS) at Argonne National Laboratory. The wavelength () of x-ray 
radiation was set as 0.886 Å. Scattered x-ray intensities were measured using a Pilatus 2M 
detector (DECTRIS Ltd). The sample-to-detector distance was set such that the detecting range 
of momentum transfer q [=4 sin/, where 2 is the scattering angle] of SAXS experiments was 
0.01-1.0 Å-1. To reduce the radiation damage, a flow cell was used and the exposure time was set 
to 1-2 seconds. The x-ray beam with size of 0.07  0.20 mm2, was adjusted to pass through the 
centers of the capillaries for every measurement. In order to obtain good signal-to-noise ratios, 
twenty images were taken for each sample and buffer. The 2-D scattering images were converted 
to 1-D SAXS curves, i.e., intensity (I(q)) vs q, through azimuthally averaging after solid angle 
correction and then normalizing with the intensity of the transmitted x-ray beam, using the 
software package developed at beamline 12ID-B. 
4.4.9 Enzymatic stability study 
Compound 7 and peptide control AcVQIVYK (1 mg/mL) were incubated with 0.1 
mg/mL pronase in 100 mM ammonium bicarbonate buffer (pH 7.8) at 37 °C for 18 h. The 
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reaction mixtures were concentrated in a speed vacuum at 60 °C to remove water and ammonium 
bicarbonate. The resulting residues were re-dissolved in water and analyzed on a Waters 
analytical HPLC system with 1 mL/min flow rate and 5% to 100% linear gradient of solvent B 
(0.1% TFA in acetonitrile) in A (0.1% TFA in water) over the duration of 40 min. The UV 
detector was set to 215 nm.  
 
(A)   (B)  
Figure 4.10 Kratky plots for peptide models with various conformation and lysozyme. (A) 
Structural bundle models taken from pdb 2FEJ, amino acid residues 277–297, total 38 
conformations. Only partial of the peptide (15 amino acids) was used in the calculation in (B). 
(B) X-ray scattering profiles, i.e., I(q) vs q, were first calculated from structural models using 
program SolX, then displayed in Kratky plots, i.e., q2*I(q) vs q. Every curve for peptides is an 
average of scattering profiles of all conformers. Peptide sequences used: red, 277-291; cyan, 
279-293; blue, 281-295; green, 283-297; magenta, 15 amino acids all in random coil 
conformation generated with molecular dynamics simulation. Well-folded macromolecules with 
MW large mass (>10kDa) often exhibits a “Bell”-shape Krakty profile at low q range, like 
lysozyme (MW=14kDa, orange curve). The peak position is a function of molecular size. The 
plateau at 0.2-0.4 Å-1 in magenta curve arises from the random coil like conformation. The peaks 
in red and cyan curves around 0.3 Å-1 arise from the helical folding. 
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CHAPTER 5: THE POTENTIAL THERAPEUTIC EFFECTS OF THC ON 
ALZHEIMER’S DISEASE 
 
 
Note to Reader 
Contents in this chapter have been previously published in Journal of Alzhermer’s 
Disease, 2014, 42(3), 973-84 and have been reproduced with the permission of the IOS press. 
5.1 Background 
In 2011 alone, 15 million family members have provided more than 17.4 billion hours of 
care to diagnosed Alzheimer’s disease (AD) patients. That care translates into more than $210 
billion of AD-related services. This disease translates into an enormous burden on caregivers, as 
well as the health care system, both medically and economically. To date, there have been no 
effective treatments developed to cure or delay the progression of AD1,2. By 2050, an estimated 
11 to 16 million Americans will be living with the disease3,4. 
AD pathology can be divided into two categories, familial inherited AD and sporadic 
AD. The histopathologies of early onset familial AD and late 40 onset sporadic AD are 
indistinguishable. Both forms of AD are characterized by extracellular amyloid-β (Aβ) peptide, 
and by amyloid plaques and tau-containing neurofibrillary tangles2. The misfolded structure of 
the Aβ peptides generates a characteristic tendency for their aggregation5. It has long been 
believed that Aβ1–40 (Aβ40) and Aβ1–42 (Aβ42) aggregates are the constituents of the 
insoluble plaques that are characteristic of AD. This disease is also associated with 
neuroinflammation, excitotoxicity, and oxidative stress6,7. However, the continuous aggregation 
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of Aβ peptides along with hyperphosphorylation of the tau protein inside the cell, causing 
neurofibrillary tangle formation, are generally accepted as the major etiological factors of the 
neuronal cell death associated with the progression of AD8-10. 
Recent studies have also suggested that glycogen synthase kinase 3 (GSK-3) has a key 
role in the pathogenesis of both sporadic and familial AD11,12. It has been reported that GSK-3β 
induces hyperphosphorylation of tau13-17. Moreover, overexpression of GSK-3 in Tet/GSK-3β 
mice reveal pathological symptoms that correspond to AD pathology with respect to spatial 
learning deficits, reactive astrocytosis, increased Aβ production, and plaque associated 
inflammation, as well as tau hyperphosphorylation resulting in Aβ-mediated neuronal death18. 
Additionally, chronic lithium (GSK-3 inhibitor) treatment in double transgenic mice 
overexpressingGSK-3β and tau has shown to prevent tau hyperphosphorylation and 
neurofibrillary tangle formation19. Some reports have also indicated that GSK-3β plays a role in 
regulating amyloid-β protein precursor (AβPPP) cleavage, resulting in increased Aβ 
production20,21. It has also been shown that the Aβ load in mouse brain can be robustly 
ameliorated by the inhibition of GSK-3β22. 
Along with past research suggesting an involvement of GSK-3 in the pathogenesis of 
AD, there have also been recent studies suggesting the intricate involvement of the cannabinoid 
system in AD. It was reported that the cannabinoid system can limit the neurodegenerative 
processes that drive the progression of the disease, and may provide a new avenue for disease 
control23. Currently the complete pathway and mechanism of action of the cannabinoid system 
are unknown, however, studies have been conducted to determine the involvement of the 
cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors in AD brain6.The CB1 receptor is 
abundant in the brain and contributes to learning, memory, and cognitive processes which are 
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interrupted early in the course of AD24. To the contrary, CB2 receptor expression is more limited 
and has been anatomically found in neurons within the brain stem25, cerebellum26, and 
microglia27. Recent research has also investigated the propensity of endocannabinoid receptor 
sub-types 1 (CB1) and 2 (CB2) to elicit a neuroprotective and anti-inflammatory effect on the 
brain when stimulated by endocannabinoids28. Postmortem studies of AD brains have detected 
increased expression of CB1 and CB2 receptors on microglia within the plaque, while CB1 
expression is reduced in neurons more remote from the plaque29. It is also noted that the 
endocannabinoid metabolizing enzyme, fatty acid amide hydrolase, is upregulated in the 
plaque30. There is also an increase in expression of anandamide metabolites, such as arachidonic 
acid, in the vicinity of the plaque30. These findings may indirectly suggest that the increase in 
CB1 109 and CB2 receptors may be to offset the lack of activity with their ligands due to 
increased metabolic activity of fatty acid amide hydrolase. These alterations in the cannabinoid 
system suggest an involvement of endogenous cannabinoids in the pathogenesis of AD or that 
this system may be altered by the pathophysiology of the disease6. Understanding that microglial 
activation is reserved in all cases of AD, it is important to identify that endogenous cannabinoids 
prevent Aβ-induced microglial activation both in vitro and in vivo31. These receptors are known 
to experience time dependent and brain region specific alterations during neurodegenerative and 
neuroinflammatory disorders to attempt to counteract excitotoxicity and inflammation32. 
Endocannabinoid receptors, CB1 and CB2, have been reported to interact with the 
endocannabinoid molecules: 2-arachidonoyl glycerol and anandamide. However, it has also been 
reported that CB1 and CB2 interact with ∆9-tetrahydrocannabinol (THC) isolated from the 
Cannabis sativa plant33. Furthermore, early reports indicate that Dronabinol, an oil-based 
solution of ∆9-THC, improves the disturbed behavior and stimulates appetite in AD patients34, 
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and alleviates nocturnal agitation in severely demented patients35. Accumulated evidence also 
suggests antioxidants having anti-inflammatory and neuroprotective roles23. 
It has also been shown that THC can decrease the level of Aβ-induced increases in 
reactive oxygen species, decreases in mitochondrial membrane potential, and caspase (a protein 
that is intimately involved in the regulation of apoptosis) activation, as well as protect human 
neurons from oligomeric Aβ-induced toxicity36. While it is understood that cannabinoids are 
active against inflammation, our research investigated the neuroprotective properties of THC, the 
active component of marijuana. Here we evaluated: 1) the effects of THC against Aβ expression 
in N2a/AβPPswe cells against the effects of caffeine, a reported Aβ expression suppressor37; 2) 
the direct effects of THC against Aβ aggregation, one pathological marker of AD; 3) the 
mechanism behind the anti-pathological properties of THC on AD; 4) the toxicity of THC and 
caffeine individually; and 5) the effects of THC on GSK-3β and other related signal pathways in 
N2a/AβPPswe cells. 
5.2 Results and Discussion 
ELISA assay was performed for Aβ40 levels in N2a/AβPPswe cells 6 hours after cells 
were treated at different concentrations individually with THC, and caffeine—a reported 
compound to lower serum Aβ40 levels in a mouse model38 —showed a significant reduction in 
Aβ40 levels of THC and caffeine versus the control (Figure 5.1A). However, 24 hours after 
treatment of N2a/AβPPswe cells, Aβ40 concentrations were measured again in the THC treated 
cells versus the control. An increasing difference in Aβ40 concentrations were noted in both 
THC treated cells and caffeine treated cells in a dose-dependent manner (Figure 5.1B). The assay 
was performed again, 48 hours after treatment of N2a/AβPPswe cells with THC versus the 
control at each concentration of the drugs originally used. THC-treated N2a/AβPPswe cells 
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significantly differed more in Aβ40 concentrations versus the control then at the 6- and 24-hour 
time point. The significant difference was conserved and greater over each increasing dose of 
THC and caffeine administered versus the control (Figure 5.1C). These data suggest THC’s and 
caffeine’s inherent anti-Aβ40 properties are time and dose dependent in N2a/AβPPswe cell 
models. This data also reveals that THC may delay of halt the progression of AD by inhibiting 
the production of Aβ40 peptide in the central nervous system. 
 
 
Figure 5.1 Dose dependent response of N2a/AβPPswe cells to THC treatment. (A) Aβ40 (pg/ml) 
in vitro measured 6 hours from incubation in N2a/AβPPswe cells. Three groups of cells were 
assayed: 1) those that were not treated with THC; 2) those that were treated with THC; and 3) 
those that were treated with caffeine. Treatment in both the THC group and in the caffeine group 
resulted in a dose-dependent decrease in Aβ40 concentration after 6 hours. There are no 
significant differences among all groups (p > 0.05). The concentrations of THC from A to F are 
0 nM, 0.25 nM, 2.5 nM, 25 nM, 250 nM, and 2500 nM respectively, and concentrations of 
caffeine from A to F are 0 M, 0.625 M, 1.25 M, 2.5 M, 5 M, and 10 M, respectively, (B) Aβ40 
(pg/ml) in vitro measured 24 hours from incubation in N2a/AβPPswe cells. A dose-dependent 
decrease in concentration of Aβ40 was still observed. THC: A, B, C, versus F are p < 0.05 and 
all other groups in comparison are p > 0.05. Caffeine: A versus B, B versus E, and all other 
groups versus F are p < 0.05. The concentrations of THC from A to F are 0, 0.25 nM, 2.5 nM, 25 
nM, 250 nM, and 2500 nM, respectively, and concentrations of caffeine from A to F are 0, 0.625 
M, 1.25 M, 2.5 M, 5 M, and 10 M, respectively, (C) Aβ40 (pg/ml) in vitro measured 48 hours 
from incubation in N2a/AβPPswe cells. A dose-dependent decrease in Aβ40 (pg/ml) in 
conserved. THC groups: p > 0.05 for A versus B, and all other groups are p < 0.05. Caffeine 
groups: p < 0.05 for B versus D, and all other comparisons between groups are p > 0.05. The 
concentrations of THC from A to F are 0, 0.25 nM, 2.5 nM, 25 nM, 250 nM, and 2500 nM, 
respectively, and concentrations of caffeine from A to F are 0, 0.625 M, 1.25 M, 2.5 M, 5 M, and 
10 M, respectively. 
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THC and caffeine were assayed for a synergistic effect on Aβ40 concentration in 
N2a/AβPPswe cells (Figure 5.2). However, no synergistic properties of THC 331 and caffeine 
are seen as there is no significant difference in the concentration of Aβ40 in N2a/AβPPswe 333 
cells solely treated with THC as compared to cells treated with 2.5 µM caffeine and THC at 
various concentrations. 
 
Figure 5.2 Aβ40 (pg/ml) concentration in N2a/AβPPswe cells at various drug concentrations 
among groups. Treatment with both THC and caffeine resulted in a dose-dependent decrease in 
Aβ40 concentration. However, no synergistic effect was observed. 
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Our data also illustrates N2a/AβPPswe cells treated with THC twice, 24 hours apart from 
each treatment, showed a significant decrease in Aβ40 concentration compared to cells treated 
once (Figure 5.3A). While the decrease in Aβ40 expression is not observed at concentration 
close to 10 µM, they are seen at 25 µM and greater suggesting multiple treatments may be 
efficacious in reducing Aβ40 concentration in N2a/AβPPswe cells and animal models. 
 
Figure 5.3 THC efficacy and toxicity studies. (A) Aβ40 (pg/ml) concentration of N2a/AβPPswe 
cells treated with THC, as well as the Aβ40 (pg/ml) concentration of N2a/AβPPswe cells treated 
with THC twice, 24 hours apart. The number of treatments has shown to decrease the 
concentration of Aβ40 (pg/ml), (B) This shows the data obtained from the reduction of MTT at 
different concentrations of THC versus the different concentration of caffeine. Untreated 
N2a/AβPPswe cells were also assayed to compare with the MTT reduction of N2a/AβPPswe 
cells treated with THC and caffeine at different concentrations. 
 
THC was also measured for toxicity versus the caffeine and the untreated N2a/AβPPswe 
cells, which served as the control. The MTT assay showed no significant difference from the 
control for toxicity as compared to each concentration of THC and caffeine administer 
suggesting THC and caffeine lack toxicity to the cells at each concentration assayed (Figure 
5.3B). 
The ThT assay was to exhibit the direct interaction THC has with Aβ demonstrates that 
as the concentration of THC added to the assay was increased, the intensity of fluorescence in 
Aβ decreased. This data suggests that Aβ peptide directly binds to THC and prevents the uptake 
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of fluorescence (Figure 5.4A). Moreover, our lab performed an additional ELISA assay to 
confirm that the interaction of the Aβ peptide with THC did not shield amino acids 1–10, the 
major B-cell epitope39 (Figure 5.4B). There is no significant difference in absorbance at each 
concentration of THC, indicating that at each concentration of THC the Aβ antibodies were able 
to bind with equal distribution and affinity. 
 
Figure 5.4 THC inhibits Aβ aggregation shown by fluorescence and ELISA assays. (A) ThT 
assay measuring the fluorescence of Thioflavin T which binds to β-sheet structure of Aβ 
aggregation. With addition of THC, dose-dependent decreases in intensity of fluorescence 
indicates THC directly interferes with the binding of ThT to Aβ peptide. (B)THC incubated with 
Aβ peptide to determine the occurrence of THC interference with the major B cell epitope. No 
identified interference was observed at each increasing concentration of THC. 
 
Therefore, we can postulate that THC’s direct interaction with the Aβ peptide will not 
dampen an immune response to clear the Aβ peptide. Further analysis with western blot was 
performed measuring the anti-aggregation properties of THC with Aβ peptide. At each 
increasing concentration of THC, a higher relative % of Aβ monomer was observed correlating 
with a lower intensity of aggregated Aβ peptide. This data suggests the direct interaction of THC 
with Aβ peptide and its ability to bind to the peptide and inhibit aggregation (Figure 5.5A,B). 
An ELISA was performed to determine the mechanism of THC in supporting the 
reduction of Aβ in N2a/AβPPswe cells. A known inhibitor of the CB1 receptor, rimonabant, was 
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mixed with THC at different concentrations. Untreated N2a/AβPPswe cell Aβ concentrations 
were used as a control. It was noted that a dose dependent increase in Aβ was observed as the 
concentration of the inhibitor was increased. A time dependent effect of the inhibitor was also 
witnessed as the assay was repeated at the 12-, 36-, 48-, 60-, and 72-hour mark (Figure 5.6). Due 
to increasing Aβ concentrations as the inhibitor concentration is increased, this suggests that 
THC partially functions through the CB1 receptor to mediate the synthesis of Aβ. The RT-PCR 
results for CB1 receptor expression level showed that there is no significant upregulation by 
THC to CB1 receptor (data not shown). 
 
 
Figure 5.5 Anti-aggregation activity of THC confirmed by western blot. (A) Polyacrylamide gel 
from a western blot indicating the concentration of aggregated Aβ peptide with and without the 
treatment of THC at various concentrations. Groups: 1: Aggregation control; 2: THC 100 nM; 3. 
THC 10 nM; 4: THC 1 nM, (B) THC anti-aggregation assay gel quantification indicating the 
relative percent monomeric Aβ. 
 
The western blot assay performed to examine the effect of THC on GSK-3β exhibits a 
dose-dependent decrease in GSK-3β. β-actin, a housekeeping gene, was used as a control to 
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indicate that GSK-3β was expressed at a constant rate and that the changes in intensity are not 
related to the change in expression amount. As shown in Figure 5.7A-D, this data suggests that 
THC is efficacious in modulating and ameliorating the expression of GSK-3β and could decrease 
neuronal apoptosis by down regulating GSK-3β. 
 
 
Figure 5.6 ELISA assay elucidating a possible mechanism through which THC functions to 
decrease the synthesis of Aβ in N2a/AβPPswe cells. Aβ level increases at 36 hours and reaches 
its peak level at 48 hours. Follow this mark; it then starts decreasing at 60 hours. The drug 
treatment benefit time is seen at 36 hours and last to 48 hours (the best window time). THC can 
significantly lower Aβ and this function can be partially blocked by CB1 antagonist Rimon at 
10−4 M. However, inhibition function is lost at 10−7 M. 
 
We detected pTau and APP levels among different treatment conditions. THC can lower 
pTau expression level with dose-dependent administration, but we did not see the differences in 
AβPP levels detected with 6E10 antibody (Figure 5.8A-F). 
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Isolated mitochondria from N2a/AβPPswe cells showed higher oxygen utilization when 
treated with THC. When combined with melatonin, the function of the mitochondria is not 
altered (Figure 5.9A, B). 
 
Figure 5.7 Down regulated GSK-3β after THC treatments. (A) A western blot performed to 
determine the effects of THC on GSK-3β in N2a/A β PPswe. β -actin was used as a control to 
indicate that the expression rate was constant. The left indicator is molecular weight. Lane 1, 2, 
and 3 are β -actin level and lane 4, 5, and 6 are GSK-3β expression. 1 and 4 are cell controls, 2 
and 5 are cells treated with 2.5 nM THC, and lane 3 and 6 are cells treated with 0.25 nM THC. 
THC can inhibit GSK-3β level at 2.4 nM concentration, (B) Graph representing the expression 
decrease in GSK-3β in a dose-dependent manner by using β -actin to obtain a value for the ratio 
of expressed GSK-3β. As shown in the bar graph, the total GSK-3β decrease after using β -actin 
standardized protein loading, (C) GSK-3β expression in N2a/A β PPswe treated with different 
drugs: Cells were plated in 6 well plate for overnight and then drugs were added into each 
designated wells in duplicate. Cells were lysed after 36 hours incubation. Proteins were loaded 
onto SDS-page gel and then blotted with each antibody after transfer onto PVDF membrane. 
Groups are: CTRL, Control; M1T2, 10−5 M Melatonin + 2.5 nM THC; M2T2, 10−6 M Melatonin 
+ 2.5 nM THC; T1, THC 25 nM; T2, THC 2.5 nM; T3, THC 0.25 nM, (D) Expression of pGSK-
3β following melatonin and THC treatment in N2a/A β PPswe cells. *The same batch protein 
samples were used in this test as in Figure 5.7C. Bands were quantified. One-way ANOVA was 
applied to the data. p < 0.05 when compared with control group. **p < 0.01 when compared with 
control group. Groups are: Ctrl, Control; M1T2, 10−5 M Melatonin + 2.5 nM THC; M2T2, 10−6 
M Melatonin + 2.5 nM THC; T1, THC 25 nM; T2, THC 2.5 nM; T3, THC 0.25 nM. 
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Figure 5.8 THC reduced the level of pTau, however it showed no effect on AβPP. (A) AβPP 
expression in N2a/AβPPswe treated with different drugs. The sample protein samples as in 
Figure 5.7C were used for western blotting assay. 6E10 anti-Aβ antibody was used to detect 
AβPP and β-Actin was detected as protein loading control. Groups are: CTRL, Control; M1T2, 
10−5 M Melatonin + 2.5 nM THC; M2T2, 10−6 M Melatonin + 2.5 nM THC; T1, THC 25 nM; 
T2, THC 2.5 nM; T3, THC 0.25 nM, (B) Quantification result of AβPP in western blotting: We 
used quantification method to further compare the differences among drug treatment to AβPP 
level. There are no statistical significant differences among all treatment (p > 0.05). This data 
indicates that THC did not change AβPP expression level. Groups are: Ctrl, Control; M1T2, 10−5 
M Melatonin + 2.5 nM THC; M2T2, 10−6 M Melatonin + 2.5 nM THC; T1, THC 25 nM; T2, 
THC 2.5 nM; T3, THC 0.25 nM, (C) Tau expression in N2a/AβPPswe treated with different 
drugs. The sample protein samples as in Figure 5.7C were used for western blotting assay. Anti-
Tau and pTau antibodies were used to detect AβPP and β-Actin was detected as protein loading 
control. Groups are: CTRL, Control; M1T2, 10−5 M Melatonin + 2.5 nM THC; M2T2, 10−6 M 
Melatonin + 2.5 nM THC; T1, THC 25 nM; T2, THC 2.5 nM; T3, THC 0.25 nM, (D) No 
significant difference of pTau expression shown among six groups in N2a/AβPPswe cells. THC 
treatment has no function to pTau expression. Groups are: Ctrl, Control; M1T2, 10−5 M 
Melatonin + 2.5 nM THC; M2T2, 10−6 M Melatonin + 2.5 nM THC; T1, THC 25 nM; T2, THC 
2.5 nM; T3, THC 0.25 nM, (E) Expression of pTau/Tau following melatonin and THC treatment 
in N2a/AβPPswe cells. +p < 0.05 when compared with THC 25 nM and THC 0.25 nM groups. 
*p < 0.01 when compared with THC 25 nM, THC 2.5 nM, and THC 0.25 nM groups. #p < 0.05 
when compared with THC 25 nM and THC 2.5 nM groups. Groups are: Ctrl, Control; M1T2, 
10−5 M Melatonin + 2.5 nM THC; M2T2, 10−6 M Melatonin + 2.5 nM THC; T1, THC 25 nM; 
T2, THC 2.5 nM; T3, THC 0.25 nM, (F) Expression of tau following melatonin and THC 
treatment in N2a/AβPPswe cells. +p < 0.05 when compared with the THC 25 nM, THC 2.5 nM, 
and THC 0.25 nM groups. **p < 0.01 when compared with the THC 25 nM, THC 2.5 nM, and 
THC 0.25 nM groups. #p < 0.05 when compared with THC 2.5 nM group. Groups are: Ctrl, 
Control; M1T2, 10−5 M Melatonin + 2.5 nM THC; M2T2, 10−6 M Melatonin + 2.5 nM THC; T1, 
THC 25 nM; T2, THC 2.5 nM; T3, THC 0.25 nM. 
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Figure 5.9 Higher oxygen utilization after THC treatment. (A) The enhancement of 
mitochondria function to cells treated with different: N2a/AβPPswe cells were cultured in 10 cm 
tissue culture plate and then treated with drugs for 36 hours and mitochondria were harvested 
and tested for their ability of using oxygen utilization. Ctrl, Control; M1T2, 10−5 M Melatonin + 
2.5 nM THC; M2T2, 10−6 M Melatonin + 2.5 nM THC; T2, THC 2.5 nM; M1, 10−5 M 
Melatonin, (B) The enhancement of mitochondria function to cells treated with different: 
N2a/AβPPswe cells were cultured in 10 cm tissue culture plate and then treated with drugs for 36 
hours and mitochondria were harvested and tested for their ability of using oxygen utilization. 
Ctrl, Control; M1T2, 10−5 M Melatonin + 2.5 nM THC; M2T2, 10−6 M Melatonin + 2.5 nM 
THC; T2, THC 2.5 nM; M1, 10−5 M Melatonin. 
 
Advances in therapeutics to prevent AD, or delay the progression, are currently being 
made. Recent research has shown caffeine and coffee are effective in limiting cognitive 
impairment and AD pathology in the transgenic mouse model by lowering brain Aβ levels, 
which are thought to be central to the pathogenesis of AD40. Similarly, the current study shows 
the in vitro anti-Aβ activity of caffeine, and of another naturally occurring compound, THC. 
N2a/AβPPswe cells were incubated separately with various concentrations of caffeine, 
melatonin, and THC. The relative anti-Aβ effect of THC was observed to increase in a time 
dependent manner. A dose-dependent decrease in Aβ concentration was noticed at lower 
concentrations of THC, as compared to caffeine. Further evidence shows that N2a/AβPPswe 
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cells, treated twice with THC, show an even greater reduction in Aβ levels at slightly higher 
concentrations. Although it might have been predicted that caffeine and THC may function in a 
synergistic effect to reduce the Aβ load in N2a/AβPPswe cells, no synergy was observed. 
The MTT assay confirmed that cells treated at efficacious concentration of THC showed 
no toxicity, suggesting such a treatment to be safe and effective for further experimentation in 
the AD animal model. However, valid arguments have transpired in recent times regarding the 
concern for acute and long-term memory impairment with the use of THC. It has been shown 
that memory impairment was identified in rats treated with THC41. It should be clear, however, 
that the memory impairment observed occurred at concentrations more than a thousand times 
higher than what is presented here as a beneficial treatment in AD model N2a/AβPPswe cells. 
The concentrations used in the study are considered to be extremely low, as the concentrations 
that we focused on in the study were from 2.5 nM of THC down to 0.25 nM of THC. Although 
some studies with ultra-low doses of THC have indicated neurotoxic roles, newer research shows 
a neuroprotective role and actually promotes elevation of phosphorylated cAMP response 
element binding protein (pCREB) by increasing the levels of brain-derived neurotrophic factor in 
the frontal cortex. Furthermore, the dosing used in our study is a lower concentration than that in 
the aforementioned research. Therefore, we believe that THC has a therapeutic value, and that at 
low enough doses, the potential benefits strongly prevail over the risks associated with THC and 
memory impairment. 
In addition to the Aβ concentration suppression, benefits of THC, analyzed with a 
western blot and ThT assay, confirmed anti-Aβ aggregate properties by a dose-dependent 
decrease in fluorescence uptake, and a decrease in intensity of aggregated Aβ in a dose-
dependent manner. The positive results suggest possible intermolecular force interactions, 
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preventing the molecular aggregation of Aβ peptides. The conducted ELISA, to ensure the 
intermolecular interaction of THC with Aβ did not block the major B-cell epitope, showed no 
interference with antibody binding, which indicated that regardless of the molecular interaction 
of THC with Aβ, an immune response should not be inhibited. 
One pathway in which THC function was shown through the cannabinoid receptor 
inhibition with rimonabant. The dose- and time-dependent increase of Aβ with respect toCB1 
inhibition was noted. It is likely that the time deference was observed due to the slow interaction 
of rimonabant with the CB1 receptor. However, the difference in Aβ concentration becomes 
more evident at the later time points. Lastly, we showed a dose-dependent decrease in GSK-3β 
expression influenced by THC. 
To date, no Aβ specific therapeutic options for AD have been approved. While 
progression is being made in this field, rigorous efforts focus on developing compounds that can 
address or possess the inhibition of Aβ synthesis and anti-Aβ aggregation properties or 
characteristics that down regulate GSK- 3β and pGSK-3β. Our results demonstrate that THC 
possesses all of the above mentioned properties. All of these areas address major etiological 
characteristics of AD. GSK-3β, pGSK-3β, and Aβ-plaque brain concentrations, the hallmark of 
AD, are major targets for current AD research. Furthermore, we have shown that THC functions 
are pathway dependent of the endogenous cannabinoid CB1 receptor recently discovered to 
possibly function in AD disease modulation by suppressing microglial activation upon receptor 
interaction. Notwithstanding, it should also be noted that low doses of THC are used to address 
the above mentioned targets, thus avoiding risks induced by THC associated with memory 
impairment and risks associated with toxicity. In addition, we also discovered that low doses of 
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THC can also enhance mitochondria function and has no negative drug interactions to melatonin, 
a potential therapeutic for AD. 
5.3 Conclusions 
Here we have presented a promising compound that addresses many major targets for AD 
therapeutics currently being research. We have shown THC, at an extremely low dose level (2.5 
nM), has the proclivity to slow or halt AD progression by dampening the synthesis of the major 
pathological marker of AD, Aβ. Also, our lab has elucidated a potential mechanism responsible 
for the anti-pathological properties of THC with respect to AD. Furthermore, we have clearly 
exhibited lack of toxicity at low concentrations of both THC and caffeine individually. In 
conclusion, we believe the multifaceted functions of THC will ultimately decrease downstream 
tau hyperphosphorylation and neuronal death thereby halting or slowing the progression of this 
devastating disease. 
5.4 Experimental Section 
5.4.1 Drugs used in this study 
THC solution was purchased from Sigma (T4764- 1ML Sigma Aldrich); caffeine was 
purchased from Sigma (C0750-100G, Sigma Aldrich); melatonin was purchased from Sigma 
(M5250-5G, Sigma Aldrich). 
5.4.2 ELISA for detection of total Aβ in protein samples 
50 µl of goat anti-PWT1-42 antibody solution was added to the sample and incubated 
overnight, followed by a 1-hour incubation with 0.1% I-block buffer. The tissue culture 
supernatant was diluted 1:10 with diluent buffer containing a protease inhibitor. Standards (1000, 
500, 250, 125, 62.5, 31.25 pg/ml) were prepared by serial dilution. The plate was washed and 50 
µl of sample or standard was added with triplication. 50 µl of both Biosource 40/42 (HS) 
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(primary antibody) Aβ and a standard solution was added to each well and incubated for 3 hours 
followed by 5×wash with PBST. 100 µl prepared secondary antibody (1:350 anti-rabbit HRP) 
was added and incubated at 37◦C for 45 minutes on a shaker. The plate was washed; TMB 
substrate was added (100µl) and incubated for 10–30 minutes in the dark. The reaction was 
halted by adding 100 µl stop solution for detection at 450 nm. A 4 parameter regression was used 
for the standard. 
5.4.3 Cell culture and drug treatment 
N2a/AβPPswe cells, N2a cells stably expressing human AβPP carrying the 
K670N/M671L Swedish mutation (AβPPswe),were grown in Dulbecco’s modified Eagle 
medium containing 10% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin, and 
400 µg/mL G418 (Invitrogen), at 37◦C in the presence of 5% CO2. N2a/AβPPswe cells were 
diluted with medium to a concentration of 2×105/ml, and plated into the each well in 3ml. 2ml of 
trypsin was incubated at room temperature, or 37 ◦C. When most of the cells began to float, 
trypsin was decanted and 5ml of fresh pre-warmed medium was added. Pipetting was performed 
more than 30 times to ensure cells were separated into individual cells. One drop of medium was 
put into 1.5 ml tubes for counting; 10 µl of trypan blue and 10 µl of medium of cells were added 
and applied to cytometer for counting. The rule was total number of cells of all for diagonal 
blocks/4X2X10000 = number of cells/ml. The proper amount of cell medium and fresh medium 
was added into new flasks according to the ratio of dilution. Pipetting was performed 10 times to 
homogenize cells. 3ml of cells were seeded into medium into each 6 well plate. When one 
pipette was used up, the cells were mixed in the flask before using them for the next pipette. 
Compounds for screening were resolved in DMSO, at 1000 fold to the final concentration in the 
well. Pipetting of 10 µl solution, then addition into 990 µl medium was performed; mixing 
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followed. 12 hours after cells were plated, 400 µl of compounds were added into 3.6 ml medium. 
The medium was then removed from the six-wells. 3ml of medium with 1% DMSO was added 
to well 1; in well 2, 3ml melatonin solution was added. In well 3, 4, 5, and 6, compound 
solutions of 3ml were added. 
5.4.4 MTT assay 
Cells were plated in 96-well tissue culture plate at 10,000 cells/well, 100 µl/well. 100 µl 
THC solution was added at 2× concentrations in each well. Control groups are: 1) cells without 
THC treatment, cells and fresh medium only; and 2) blank, wells with medium without cells. All 
wells were replicated. Wells were incubated for 36 hours. Cell proliferation kit (Roche 
11465007001) was then applied for toxicity assay according to the standard protocol. 10 µl of 
MTT 226 reagent was first added to each well and incubated at 37 ◦C for 4 hours. Then 100 µl of 
solubilization solution was added to each well. These were incubated overnight and optical 
density (OD) values were read at 575 nm. The percentage of cell viability was calculated as: Cell 
viability% = (OD – OD blank) / (OD control – OD blank) 
5.4.5 Western blot for anti-aggregation assay 
HFIP pretreated Aβ1-40 peptide were obtained from Biomer Technology, California. 
Aβ1-40 peptide solution was prepared in Ham’s F-12 solution to concentrations of 200 µM as 
stock. In the 15 µl aggregation system: 1) THC at final concentration of 25 nM, 2.5 nM, or 0.25 
nM; and 2) 1.5 µl peptide stock solution was added. Then 15 µl with F-12 medium was made. 
Aggregation was allowed for 48 hours at 37 ◦C. After incubation, isomers of Aβ peptide were 
separated by 12% Tris-Tricine gel electrophoresis at 100V for 180–210 minutes, a temperatures 
under 4 ◦C. The protein was transferred to PVDF membrane with semi-dry transfer at 200mA for 
70 minutes. For western blot detection, the membrane was blocked with 1.5% BSA solution in 
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PBST solution (0.5%), then incubated in 1st Antibody: 6E10 (Signet) 1mg/ml, diluted by 1:1000 
dilution in blocking buffer. It was then washed 3 times with 1× PBST solution, and then 
incubated with second antibody (anti-mouse IgG254 HRP sigma A9044. 1:5000 diluted in 
blocking buffer). After membrane was developed, film with bands were scanned, followed by 
analysis of gel-quantification software (QuantityOne, from Bio-rad). 
5.4.6 Thioflavin T fluorescence assay 
HFIP pretreated Aβ1-40 peptide was obtained from Biomer Technology, California. In 
thioflavin T (ThT) solutions (1.6 µg/ml dissolved in 20mM Tris-HCl), THC solution was 
prepared at concentration of 250, 25, 2.5, and 0.25 nM. THC solution was added containing ThT 
buffer into black 96 well plates. Unaggregated Aβ peptide solution was thawed, diluted, and 
immediately added to wells, making the final concentration of Aβ1-40 at 1 µM. Control groups 
were setup as: 1) aggregation control; 2) control with ThT buffer only; and 3) Tris-HCl buffer 
only. Plate was mixed and fluorescence was read at 482 nm with excitation 440 nm with Biotek 
All-in-One plate reader. Fluorescence was screened for 2 hours with 5-minute intervals. 
5.4.7 Western blot for total and phosphorylated GSK-3β, total tau and phosphorylated tau, and β-
actin 
Followed by THC treatment in tissue culture, N2a/AβPPswe cell lysate were collected, 
quantified, and aliquoted. Using 12% Tris-Glycine gel system (Biorad), protein were separated 
by electrophoresis and semi-dry transferred to PVDFmembrane.GSK-3β and β-actin antibodies 
were used as primary antibody. After adding secondary antibody, the membranes were exposed 
using ECL substrate (Pierce). After membrane was developed, film with bands were scanned, 
followed by analysis of gel-quantification software (QuantityOne, from Biorad). 
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5.4.8 Mitochondria isolation and respiratory measurements 
The respiratory function of isolated mitochondria was measured using a miniature Clark 
type oxygen electrode (Strathkelvin Instruments, MT200A chamber, Glasgow, UK). Detail 
method is published in Dragicevic et al.42. 
5.4.9 Statistical analysis and graphs 
All data were analyzed with one-way ANOVA and post hoc analysis was conducted with 
Turkey’s group analysis and p < 0.05 was considered as statistical significance (GraphPad 6.0). 
All graphs were graphed with GraphPad 6.0 software. 
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APPENDIX A: 1H AND 13C NMR SPECTRA 
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